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 Cystic Fibrosis (CF) is the most common lethal recessive genetic disorder in the Caucasian 
population, affecting about 90,000 people worldwide. CF is caused by mutations in the Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) gene which encodes a chloride (Cl-) and bicarbonate 
(HCO3
-
) anion channel that is located in the apical side of epithelial cells. The lack of function of mutant 
CFTR leads to an impairment of anion transport and, consequently, of fluid secretion, resulting in a 
dysregulation of fluid homeostasis and osmolarity across several epithelia. This means that CF causes 
several symptoms that include chronic inflammation and infection of the airways, gastrointestinal tract 
perturbations, pancreatic insufficiency and infertility. It also affects tissue regeneration and epithelial 
differentiation, resulting in tracheal malformations, delayed wound healing, altered gland secretion and 
compromised barrier function of several epithelia. However, it is the airways disease, characterized by low 
height of the airway-surface liquid (ASL) and thick mucus that impairs mucociliary clearance leading to 
chronic inflammation and infections progressively deteriorating lung function, which remains the major 
cause of morbidity and mortality among individuals with CF.   
 Since the discovery of the CFTR gene, over 2,000 different mutations have been reported and 
most presumed to be CF-causing, so a classification system was created, consisting of seven classes (I-
VII) into which CFTR mutations are grouped according to the molecular/cellular defect they elicit. This 
classification also evolved to assist in drug discovery. Indeed, since mutations in the same class share the 
same basic molecular defect, a common therapeutic strategy should rescue all mutations in the same class. 
In the past few years, small-molecule drugs were approved which (alone or combined) rescue mutant 
CFTR with specific mutations. The first, VX-770 (Ivacaftor), is used as a potentiator of the CFTR 
channel, and thus applies to individuals with CF who have gating or conductance mutations (classes III 
and IV). When in combination with a CFTR corrector, VX-809 (Lumacaftor) or VX-661 (Tezacaftor), that 
rescue the defective traffic of CFTR with the most prevalent CF-causing mutation (F508del),  it applies to 
individuals with CF who are F508del-homozygous. However, individuals with CF who do not carry any 
of these mutations may still get clinical benefit from their administration. Moreover, there are also 
individuals with CF who have the mutations for which the drugs were designed but who do not benefit 
from them, probably due to other factors, such as modifier genes and environmental factors. Thus, a 
personalized medicine approach, termed theranostics (therapeutic diagnostics) is becoming an important 
approach to bring the right drugs to the individuals who can benefit from them. To this end, several ex 
vivo models have been used to assist in the laboratory testing of these drugs, including primary human 
nasal and bronchial epithelial (HNE/HBE) cells as well as intestinal crypts that are used to create 3D-
intestinal organoids. More recently, another model was developed through the culturing of 2D-monolayers 
of intestinal epithelial cells derived from these 3D-organoids, hereby opening a vast array of possibilities 
for CFTR function assessment. Indeed, if shown to recapitulate in vivo CFTR function, these organoid-
derived 2D-monolayers hold promise for replacing or complementing 3D-intestinal organoids and fresh 
biopsies. The latter in particular are used for CF diagnosis/prognosis but, in centres where immediate 
electrophysiological analysis of biopsies is not possible, to ship them to reference centres is impossible 
due to their short-term viability for electrophysiology (~6h). Nevertheless, fresh biopsies maintain their 
feasibility to generate 3D-organoids over a 24-h period and thus can be shipped to reference centres which 
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can then generate 3D- and 2D monolayers and analyze the latter in direct Ussing chamber measurements. 
Notwithstanding, because 2D-monolayers are a new model system, it is still poorly characterized as well 
as their usage in CF diagnosis/prognosis and in determining responsiveness to drugs. 
 The main goals of this MSc project were: 
1) to characterize the novel 2D-intestinal cellular system by assessing: 
a. The expression levels of plasma membrane (PM) proteins and ion channels present in the 
native tissue which are essential for Cl
- 
secretion;  
b. The differentiation status and progress of the 2D-intestinal epithelial monolayers by 
differentiation and proliferation markers under differentiation and non- differentiation 
conditions.  
2) to compare CFTR function in native tissues and primary cultures derived from individuals with 
CF and non-CF controls by: 
a. Ussing chamber measurements of CFTR-mediated Cl- secretion in fresh rectal biopsies; 
b. Forskolin-induced swelling (FIS) assay of intestinal 3D-organoids derived from rectal 
biopsies; 
c. Ussing chamber measurements of 2D-intestinal monolayers. 
3) To establish correlations between: 
a. Values obtained in 2a, 2b and 2c for the same individuals as well as with other CF 
biomarkers from these individuals, in order to assess if 2D-intestinal monolayers 
recapitulate the properties of the more established models in predicting disease severity so 
as to validate them as good personalized cell models for CFTR function and thus for CF 
diagnosis/prognosis; 
b. Values obtained in 2b and 2c for the same individuals to determine whether 2D-intestinal 
monolayers recapitulate the CFTR modulator drugs found in 3D-organoids and thus 
assess whether they constitute a good model to predict individuals’ drug responses.  
 Our results on the differentiation of the 2D-monolayers showed a low expression of CFTR protein 
in the late differentiation stages and high levels of CFTR expression and function in the less differentiated 
monolayers. This finding has led us to use the less differentiated monolayers in our subsequent 
measurements of Cl
-
 secretion. Moreover, we established good correlations among function parameters 
measured in the 2D-monolayers, the 3D-organoids and the fresh rectal biopsies, showing that 2D-
monolayers are good models to assess CFTR function in vivo. Importantly, our results also showed good 
correlations between measurements of CFTR function in 2D-monolayers and other CF biomarkers such as 
fecal elastase. The assays used to analyze rescue of CFTR function with modulators showed significant 
rescue in 4 out of 7 individuals analyzed. 
 Overall, these results show that the 2D-monolayers seem to be a good model to replace or 
complement the 3D-organoids and rectal biopsies to assess CFTR function. However, they should be 
further studied in more individuals with different mutations. Additionally, this 2D-model could assist in 
providing a precision medicine approach to individuals with CF, in order to give the right drug to the right 
individual because, in contrast to fresh rectal biopsies, they evidence responses to CFTR modulators. 






 A Fibrose Quística (FQ) é a doença genética recessiva mais comum na população caucasiana, 
afetando cerca de 90,00 pessoas em todo o mundo. A FQ é causada por mutações no gene que codifica a 
proteína CFTR (do inglês, Cystic Fibrosis Transmembrane Conductance Regulator)), que é um canal de 
aniões cloreto (Cl
-
) e bicarbonato (HCO3
-
) e que está presente na membrana apical das células epiteliais. A 
perda de função da CFTR mutada leva à ausência de secreção de aniões e, consequentemente, da secreção 
de fluido, resultando numa desregulação da homeostase do fluido e da osmolaridade nos diferentes 
epitélios. Assim, a FQ é uma doença que afecta múltiplos sistemas e causa várias manifestações clínicas 
tais como, infeções pulmonares recorrentes, insuficiência do pâncreas exócrino, diabetes relacionada com 
a FQ, distúrbios gastrointestinais, doença hepática, doença renal crónica e infertilidade masculina. 
Também é uma doença que afeta a reconstituição dos tecidos e a diferenciação epitelial e por isso 
indivíduos com FQ apresentam malformações na traqueia, alterações na regeneração celular, secreções 
glandulares anómalas e alterações na permeabilidade de vários tecidos epiteliais. No entanto, a doença das 
vias respiratórias, caracterizada pelo aumento da viscosidade do muco que dificulta a clearance muco-
ciliar e ao aumento da incidência das infeções respiratórias graves e processos inflamatórios que 
progressivamente reduzem a função respiratória, permanece a principal causa de mortalidade dos 
indivíduos com FQ.   
 Desde a descoberta do gene CFTR em 1989, mais de 2,000 mutações foram descritas, a maioria 
das quais presumivelmente causadora de FQ. Assim, para melhor as caracterizar, foi proposto um sistema 
de classificação, consistindo em sete classes (I-VII), onde as mutações da CFTR são agrupadas de acordo 
com o defeito molecular/celular que provocam. A classe I consiste em mutações que geram codões stop 
prematuros levando à produção de proteínas truncadas que são degradadas pelo proteassoma. As mutações 
de classe II causam um defeito de folding da proteína CFTR e a sua subsequente retenção no retículo 
endoplasmático e degradação, impedindo o seu tráfego para a membrana plasmática (MP). A mutação 
F508del, a mais comum na FQ, faz parte desta classe. As mutações de classe III afectam a regulação do 
canal CFTR diminuindo a sua probabilidade de abertura. Mutações de classe IV provocam 
constrangimentos no poro da CFTR e, por conseguinte, uma redução drástica na condutância do canal. 
Mutações de classe V levam a uma redução nos níveis de CFTR, normalmente provocada por mecanismos 
de splicing alternativo que dão origem a transcritos normais e aberrantes em proporções diferentes. 
Mutações de classe VI reduzem a estabilidade da CFTR na MP, levando à sua internalização e 
degradação. Por fim, mutações de classe VII levam à perda por completo da expressão do gene CFTR 
geralmente devido a grandes deleções e, por isso, são chamadas de “irrecuperáveis” pois não podem ser 
tratadas farmacologicamente para recuperação da função da CFTR. Este sistema de classificação foi 
evoluindo no sentido de auxiliar no desenvolvimento de fármacos. Com efeito, já que mutações da mesma 
classe causam o mesmo defeito molecular, uma mesma estratégia terapêutica deverá tratar todas as 
mutações da mesma classe. Recentemente, foram aprovados fármacos consistindo em pequenas moléculas 
que (sozinhas ou em combinação) fazem o resgate da proteína CFTR com mutações específicas. O 
primeiro, VX-770 (Ivacaftor), é usado como potenciador do canal CFTR e está aprovado para mutações de 
classe III e algumas mutações de classe IV. Atualmente, é utilizado também em combinação com 
corretores da CFTR, como o VX-809 (Lumacaftor) ou o VX-661 (Tezacaftor), que corrigem o defeito de 
tráfego para a MP. Estes corretores foram desenvolvidos para a mutação mais comum - F508del-CFTR. 
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No entanto, indivíduos que não possuem as mutações para as quais se aplicam os moduladores podem 
também ter benefício clinico da sua administração. Além disso, existem indivíduos que têm as mutações 
para as quais estes fármacos se aplicam, mas que não demonstram benefício após administração dos 
mesmos. Tal é devido a outros fatores, tais como genes modificadores e fatores ambientais. Logo, uma 
abordagem de medicina personalizada designada teranóstico (do inglês, therapeutic diagnostics) torna-se 
cada vez mais importante para trazer o fármaco certo para os indivíduos que dele podem receber 
benefício. Para tal, têm sido criados modelos celulares ex vivo para auxiliarem em ensaios laboratoriais de 
previsão de eficácia destes fármacos. Estes modelos, gerados a partir de materiais biológicos derivados 
dos indivíduos, incluem células dos epitélios nasal ou brônquico (de lavagens bronquiais ou de pulmões 
transplantados) ou células intestinais obtidas de biopsias rectais. Estas últimas têm sido utilizadas para 
gerar organóides intestinais tridimensionais (3D) usados para testar o efeito dos moduladores da CFTR. 
No entanto, mais recentemente, foi criado um novo modelo através do cultivo de monocamadas 
bidimensionais (2D) de células epiteliais intestinais obtidas a partir dos organóides 3D. Estes sistemas 
celulares 2D abrem novas possibilidades para o teste de moduladores da CFTR. Com efeito, se se 
demonstrar que recapitulam a função basal da CFTR in vivo em medições de secreção de Cl- em 
microcâmaras de Ussing, estes sistemas celulares 2D têm elevado potencial para substituir ou 
complementar os organóides intestinais 3D e as biopsias rectais frescas. Estas últimas em particular são 
usadas para diagnóstico/prognóstico da FQ, mas em centros onde não é possível a sua análise imediata por 
eletrofisiologia, não é possível o seu envio para centros de referência, dado o curto espaço de tempo em 
que se mantêm viáveis para eletrofisiologia (~6h). Porém, as biopsias frescas mantêm a sua viabilidade 
para gerar organóides 3D durante 24h, sendo assim possível o seu envio para centros de referência onde se 
pode produzir organóides 3D e monocamadas 2D, estas últimas para análise direta em camara de Ussing. 
No entanto, uma vez que as monocamadas 2D são sistema modelo novo, estão pouco caracterizadas, não 
tendo sido ainda demonstrada a sua aplicabilidade para diagnóstico/prognóstico da FQ ou para testar o 
efeito e eficácia dos fármacos moduladores CFTR. 
Os principais objetivos deste projeto de mestrado eram: 
1) A caracterização do novo modelo em estudo, as monocamadas 2D, avaliando: 
a.  A expressão de proteínas de membrana e canais iónicos presentes no tecido nativo e 
essenciais para a secreção de Cl
-
; 
b.  A diferenciação das células epiteliais intestinais por marcadores de diferenciação e 
proliferação, em condições de não diferenciação e de diferenciação. 
2) A análise da função da CFTR em tecidos nativos e em culturas de células primárias de indivíduos 
com FQ, comparando com controlos normais através de: 
a. Medição em microcâmaras de Ussing da secreção de Cl- mediada pela CFTR em biopsias 
rectais frescas; 
b. Ensaios de inchamento mediado por Forscolina (FIS) em organóides intestinais 
provenientes das biopsias rectais; 
c. Medição em microcâmaras de Ussing da função da CFTR em monocamadas 2D de 
células epiteliais intestinais derivadas dos organóides 3D; 
3) Estabelecer correlações entre: 
a.  Os valores obtidos em 2.a, 2b e 2c para os mesmos indivíduos e com os outros 
biomarcadores da FQ destes indivíduos, com o intuito de validar as monocamadas 2D de 
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células epiteliais intestinais como um bom modelo celular personalizado para a medição 
da função da CFTR e consequentemente para diagnóstico/prognóstico da FQ. 
b. Os valores obtidos em 2b e 2c para os mesmos indivíduos para avaliar se as últimas 
recapitulam as respostas aos fármacos moduladores CFTR observadas em organóides 3D 
e assim determinar se as monocamadas 2D são um bom modelo para a previsão da 
resposta a estes fármacos.  
 Os resultados do estudo da diferenciação das monocamadas 2D mostraram que existe uma perda 
de expressão de CFTR nas células diferenciadas e uma elevada expressão e função de CFTR nas 
monocamadas 2D não diferenciadas. Por isso, ao longo to trabalho, usámos as monocamadas 2D não 
diferenciadas nas medições de secreção de Cl
- 
em microcâmaras de Ussing. 
 Estabelecemos boas correlações entre a função de CFTR medida nas monocamadas 2D, nos 
organóides 3D e nas biopsias retais. Os nossos resultados mostraram que a função basal máxima da CFTR 
medida nas monocamadas 2D (2D ΔIsc-eq (max)) se correlaciona com a mesma ativação máxima medida 
nas biopsias rectais (Biopsy ΔIsc-eq (max)) e com as medições de inchamento ‘basal’ dos organóides 3D, 
i.e., só com forscolina (AUC [Fsk] = 0.8). Por fim, ainda estabelecemos correlações entre medições de 
função de CFTR em monocamadas 2D e outros biomarcadores de FQ, nomeadamente mostrámos que 
existe uma correlação entre a secreção de Cl
-
 ativada pelo cAMP e co-ativada colinergicamente nas 
monocamadas 2D (2D ΔIsc-eq (max)) com o valor de elastase fecal E1 nos indivíduos com FQ. 
 Os ensaios de FIS permitiram-nos concluir que existe função residual da CFTR em 3 dos 6 
indivíduos em que os organóides foram estudados e foi possível prever benefício clínico em 5 desses 6 
indivíduos com pelo menos um fármaco modulador da CFTR testado. Os nossos ensaios de resgate de 
função de CFTR com moduladores da CFTR em monocamadas 2D permitiram-nos encontrar resposta 
significativa em 4 dos 7 indivíduos testados. 
Em suma, estes resultados aqui apresentados demonstram que há um potencial na aplicação do modelo de 
células intestinais 2D para substituir ou complementar os ensaios realizados nos organóides 3D e nas 
biopsias rectais frescas. Uma aplicação muito importante deste novo modelo será na “medicina 
personlizada”, ou teranóstico no qual as monocamadas 2D seriam usadas para prever qual a terapia mais 
adequada para um determinado indivíduo com FQ. Para uma validação mais profunda deste modelo, no 
futuro, mais ensaios deveriam ser realizados com monocamadas 2D de maior número de indivíduos com 
FQ com diferentes mutações. 







Table of Contents 
 
Acknowledgements ..................................................................................................................................... iii 
Summary ..................................................................................................................................................... iv 
Resumo ........................................................................................................................................................ vi 
Index of Figures and Tables ....................................................................................................................... xii 
List of Acronyms and Abbreviations .......................................................................................................... xv 
1. Introduction ..........................................................................................................................................1 
1.1 Cystic Fibrosis ..............................................................................................................................1 
1.2 CFTR ............................................................................................................................................3 
1.2.1 Structure and Regulation of CFTR Protein ...........................................................................3 
1.2.2 Functional Classification of CFTR Mutations and Theratypes .............................................5 
1.2.3 CFTR and Epithelial Differentiation .....................................................................................6 
1.3 Current Diagnosis Methods for CF ...............................................................................................7 
1.3.1 Sweat Chloride Concentration Test ......................................................................................7 
1.3.2 Nasal Potential Difference (NPD).........................................................................................8 
1.3.3 CFTR Genotyping ................................................................................................................8 
1.3.4 Newborn Screening Programs ..............................................................................................9 
1.3.5 Cl- current measurements using rectal biopsies in Ussing chambers.....................................9 
1.4 CF Personalized Therapies .........................................................................................................10 
1.4.1 Primary Human Bronchial/Nasal Epithelial Cells ...............................................................10 
1.4.2 Nasospheroids.....................................................................................................................11 
1.4.3 3D Intestinal Organoids ......................................................................................................11 
1.4.4 2D Intestinal Monolayers....................................................................................................12 
2. Objectives ...........................................................................................................................................14 
3. Materials and Methods .......................................................................................................................15 
3.1 Cell Culture ................................................................................................................................15 
3.1.1 Culture conditions of the human intestinal organoids .........................................................15 
3.1.2 Culture conditions of the 2D intestinal monolayers ............................................................16 
3.2 Functional CFTR analysis ..........................................................................................................17 
3.2.1 Measurement of CFTR Mediated Cl- Secretion in Rectal Biopsies.....................................17 
x 
 
3.2.2 Measurement of CFTR Mediated Cl- Secretion in 2D Intestinal Monolayers .....................17 
3.2.3 Forskolin-induced swelling assay .......................................................................................18 
3.3 Expression Analysis ...................................................................................................................19 
3.3.1 Gene Expression Analysis ..................................................................................................19 
3.3.1.1 RNA Purification ............................................................................................................19 
3.3.1.2 cDNA Synthesis .............................................................................................................19 
3.3.1.3 RT-PCR ..........................................................................................................................19 
3.3.2 Western Blot .......................................................................................................................21 
3.4 Statistical Analyses .....................................................................................................................22 
4. Results and Discussion .......................................................................................................................23 
4.1 Description of Phenotypes of Individuals with CF .....................................................................23 
4.2 Characterization of the 2D Intestinal Monolayers ......................................................................23 
4.2.1 Gene Expression Analysis Comparison Among Models.....................................................24 
4.2.2 Biochemical Characterization During Differentiation of the 2D Intestinal Epithelial 
Monolayer ..........................................................................................................................................26 
4.2.3 Analysis of WT CFTR Basal Activity Using Ussing Chamber Experiments in 2D Intestinal 
Cell Cultures.......................................................................................................................................28 
4.3 Comparison of CFTR Function Assessment Between Rectal Biopsies and 2D Intestinal 
Monolayers.............................................................................................................................................29 
4.3.1 WT......................................................................................................................................30 
4.3.2 Residual CFTR Function Mutations ...................................................................................33 
4.3.2.1 F508del/S955P................................................................................................................33 
4.4.2.2 F508del/R347P ...............................................................................................................34 
4.4.2.3 F508del/R334W..............................................................................................................35 
4.4.3 Severe CFTR Mutations .....................................................................................................37 
4.4.3.1 F508del/G542X ..............................................................................................................37 
4.4.3.2 F508del/F508del .............................................................................................................38 
4.4.3.3 F508del/A561E ...............................................................................................................41 
4.4 Comparison of CFTR Functional Rescue Between 2D and 3D Models .....................................43 
4.4.1 Residual CFTR Function Mutations ...................................................................................43 





4.4.2 Severe CFTR Mutations .....................................................................................................50 
4.4.2.1 F508del/G542X ..............................................................................................................50 
4.4.2.2 F508del/F508del .............................................................................................................51 
4.4.2.3 F508del/A561E ...............................................................................................................55 
4.5 Correlations of CFTR Function Parameters and Clinical Data among Fresh tissue, 3D and 2D 
models 58 
4.5.1 Correlations between 2D Model and Fresh Tissue ..............................................................60 
4.5.2 Correlations between 2D- and 3D-models ..........................................................................61 
4.5.3 Correlations between Different CFTR Function Parameters Measured in the 2D 
Monolayers with Clinical Data and Established CF Biomarkers ........................................................64 
5. Conclusion and Future Perspectives ...................................................................................................67 













Index of Figures and Tables 
 
Figure 1.1 - Effects of CFTR functional deficiency in the airway epithelium. .............................................2 
Figure 1.2 - Structure of the human CFTR in the dephosphorylated, ATP free conformation. A. ................4 
Figure 1.3 – Scheme of CFTR molecular mechanism. .................................................................................5 
Figure 1.4 – Summary of all seven CFTR functional mutation classes and respective therapeutic strategies.
 .....................................................................................................................................................................6 
Figure 1.5 – Nasal potential difference measurement in (A) a healthy individual and (B) a person with 
classic CF. ....................................................................................................................................................8 
Figure 1.6 – Three possible micro-Ussing chamber readouts for the assessment of CFTR function and the 
distinction between subtypes of individuals. ..............................................................................................10 
Figure 1.7 – Crypt structure, cell composition and distribution in the colon crypts.  ..................................11 
Figure 1.8 – Forskolin-induced swelling assay. ..........................................................................................12 
Figure 1.9 – Histological section of the 2D intestinal monolayers derived from 3D intestinal organoids.  13 
Figure 3.1 – Schematic representaion of organoid generation from plated intestinal crypts from rectal 
biopsies. .....................................................................................................................................................16 
Figure 4.1 - Gene expression analysis of CFTR and related membrane proteins and ion channels, and 
differentiation markers. ..............................................................................................................................25 
Figure 4.2 – WB analysis of WT 2D undifferentiated and differentiated monolayers and 3D organoids. ..27 
Figure 4.3 – Results from Ussing chamber measurements for basal activity in 2D-intestinal monolayers 
from a WT donor. .......................................................................................................................................28 
Figure 4.4 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from a 
WT donor. ..................................................................................................................................................31 
Figure 4.5 - Results from Ussing chamber measurements in differentiated 2D-monolayers from a WT 
donor. .........................................................................................................................................................32 
Figure 4.6 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from 
patient CFL59 (F508del/S995P genotype). ................................................................................................34 
Figure 4.7 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from 
patient CFL54 (F508del/R347P genotype). ................................................................................................35 
Figure 4.8 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from 
patient CFL75 (F508del/R334W genotype). ..............................................................................................36 
Figure 4.9 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from 
patient CFL61 (F508del/G542X genotype). ...............................................................................................37 
Figure 4.10 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from 
patient CFL65 (F508del/F508del genotype). ..............................................................................................39 
Figure 4.11 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from 
patient CFL80 (F508del/F508del genotype). ..............................................................................................40 
Figure 4.12 - Results from Ussing chamber measurements in differentiated 2D-monolayers from patient 
CFL80 (F508del/F508del genotype). .........................................................................................................41 
Figure 4.13 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from 
patient CFL70 (F508del/A561E genotype). ...............................................................................................42 
xiii 
 
Figure 4.14 – Results from the FIS assay on 3D-intestinal organoids from patient CFL54 (F508del/R347P 
genotype)....................................................................................................................................................44 
Figure 4.15 – Results from Ussing chamber measurements in 2D-intestinal monolayers from patient 
CFL54 (F508del/R347P genotype). ...........................................................................................................45 
Figure 4.16 – Results from the FIS assay on 3D-intestinal organoids from patient CFL59 (F508del/S995P 
genotype)....................................................................................................................................................46 
Figure 4.17 – Results from Ussing chamber measurements in 2D-intestinal monolayers from patient 
CFL59 (F508del/S995P genotype). ............................................................................................................47 
Figure 4.18 – Results from the FIS assay on 3D-intestinal organoids from patient CFL75 (F508del/R334W 
genotype)....................................................................................................................................................48 
Figure 4.19 – Results from Ussing chamber measurements in 2D-intestinal monolayers from patient 
CFL75 (F508del/R334W genotype). ..........................................................................................................49 
Figure 4.20 – Results from Ussing chamber measurements in 2D-intestinal monolayers from patient 
CFL61 (F508del/G542X genotype). ...........................................................................................................50 
Figure 4.21 – Results from the FIS assay on 3D-intestinal organoids from patient CFL65 
(F508del/F508del genotype). .....................................................................................................................52 
Figure 4.22 - Results from Ussing chamber measurements in 2D-intestinal monolayers from patient 
CFL65 (F508del/F508del genotype). .........................................................................................................53 
Figure 4.23 – Results from the FIS assay on 3D intestinal organoids from patient CFL80 
(F508del/F508del genotype). .....................................................................................................................54 
Figure 4.24 - Results from Ussing chamber measurements in 2D-intestinal monolayers from patient 
CFL80 (F508del/F508del genotype). .........................................................................................................55 
Figure 4.25 - Results from the FIS assay on 3D-intestinal organoids from patient CFL70 (F508del/A561E 
genotype)....................................................................................................................................................56 
Figure 4.26 - Results from Ussing chamber measurements in 2D-intestinal monolayers from patient 
CFL70 (F508del/A561E genotype). ...........................................................................................................57 
Figure 4.27 – Correlation between CCH-induced short circuit currents following IBMX/Fsk 
administration to 2D-monolayers and rectal biopsies. ................................................................................61 
Figure 4.28 - Correlation between CCH-induced short circuit currents following IBMX/Fsk administration 
to 2D-monolayers and the AUC of organoid swelling at [Fsk] = 0.8 µM. ..................................................63 
Figure 4.29 - Correlation between VX-770-induced short circuit currents following IBMX/Fsk in VX-661 
treated 2D-monolayers and the AUC of VX-661/770-treated organoid swelling at [Fsk] = 5 µM. ............64 
Figure 4.30 – Correlation among IBMX/Fsk-induced short circuit currents and CCH-induced short circuit 
current following IBMX/Fsk, and individuals’ FEE values. ......................................................................66 
 
Table 3.1 – Reagents used in the PCR reactions.........................................................................................20 
Table 3.2 – PCR programme used in the PCR reactions. ...........................................................................20 
Table 3.3 – Primer sequences used for each gene studied in this work and annealing temperature of each 
primer. ........................................................................................................................................................20 
Table 3.4 – Primary antibodies used in this work. ......................................................................................21 
Table 3.5 – Secondary antibodies used in this work. ..................................................................................22 
Table 4.1 – Overview of data from individuals with:  ................................................................................23 
xiv 
 
Table 4.2 – Summary of 3D intestinal organoids and 2D intestinal monolayer analyses for all individuals 
studied. . .....................................................................................................................................................57 
Table 4.3 – Summary of all data used for the correlation studies.. .............................................................59 
Table 4.4 – Correlation data between activated short circuit currents measured in 2D-monolayers and 
rectal biopsies.. ...........................................................................................................................................60 
Table 4.5 – Correlation analyzes between activated short circuit currents measured in 2D-monolayers and 
organoid swelling. ......................................................................................................................................62 
Table 4.6 – Correlation data between the activated short circuit currents measured in the 2D monolayers 























List of Acronyms and Abbreviations 











































Analysis of variance 
Ammonium persulfate 
Area under the curve 
Large conductance 
Cyclic adenosine monophosphate 
Carbachol 
Cystic Fibrosis 
Cystic Fibrosis Transmembrane Conductance Regulator 




Epithelial sodium channel 
Endoplasmic reticulum 
ER associated degradation 
Advanced DMEM/F12 + 1% Pen/Strep + 1% Glutamax + 1% HEPES 
Fecal elastase E1 
Forskolin-induced swelling 
Forskolin 
Human bronchial epithelial cell 
Human nasal epithelial cell 
Horse-radish peroxidase 
3-isobutyl-1-methylxanthine 




Immunoreactive trypsin assay 
Leucine rich repeat-containing G protein coupled receptor 5 
Mucociliary Clearance 
N-cadherin  































 Cotransporter 1 
Nasal potential difference 




Protein kinase A 
Plasma membrane 
Premature stop codon 
Regulatory domain 
Resistance 
Reverse transcriptase polimerase chain reaction 
Standard deviation 































1.1 Cystic Fibrosis 
 
 Cystic Fibrosis (CF) is the most common recessive genetic disorder, affecting around 45,000 
individuals in Europe and about 90,000 worldwide
1–3
. It is caused by mutations in the CF 
transmembrane conductance regulator (CFTR) gene, which encodes a cAMP-regulated chloride (Cl-) 
and bicarbonate (HCO3
-
) anion channel located in the apical side of epithelial cells
4,5
. Since its 
discovery and sequencing in 1989
6
, over 2,000 different mutations have been identified so far 
(http://genet.sickkids.on.ca/StatisticsPage.html), most of which presumed to be CF-causing 
(www.cftr2.org). The most frequent mutation – F508del – is present in ~80% of individuals 
worldwide in, at least, one allele
2
. 
 CF is a multisystem disease, affecting different organs and tissues, which causes several clinical 
manifestations, such as recurrent pulmonary infections and inflammation, exocrine pancreas 
insufficiency, CF-related diabetes, gastrointestinal disorders (including meconium ileus in the 
neonatal period),  liver disease, chronic kidney disease and infertility in both male and female 
individuals
2,7
. However, irreversible lung damage caused by chronic obstructive lung disease is still 
the main cause of morbidity and cause of death of 85% of individuals with CF
8
.  
 For the pathophysiology of the lung disease, CFTR interactions with other proteins, such as the 
epithelial sodium channel (ENaC)
9









hyper-absorption. Ultimately, this leads to severe epithelial dehydration in the airways and impedes 
mucociliary clearance (MCC)
10–12
. However, besides osmotic regulation, CFTR regulates the pH of 




. Impairment of HCO3
-
 transport lowers the pH of 
the mucosa, which leads to a more viscous mucus
16,17
 and contributes negatively to the function of 
anti-microbial peptides, contributing to an increase in infections prevalence
18
. As lung disease 
progresses, bronchiectasis settles and individuals with CF experience several infections from Gram 










 anion secretion also affects the epithelial cells of 
the pancreas and the biliary duct. Mucus plugging affects the secretion of the digestive enzymes by 
the acinar cells to the small intestine. The enzymes remain clogged in the pancreatic ducts and start to 
damage the pancreatic tissue
20,21
. The obstruction occurs early in uterus, so individuals with classical 
CF develop pancreatic insufficiency (PI) at birth or soon after, while individuals with some CFTR 
residual function develop PI later in life
22,23
. This PI can be surpassed with the help of pancreatic 
enzyme replacement therapy
21,24
. Apart from that, the lack of HCO3
-
-rich fluid secreted by the 
pancreas combined with CFTR deficiency in the proximal intestine causes poor digestive function in 
the intestine due to the ineffective neutralization of gastric fluids
25
. There is a strong correlation of 
deterioration of lung function and poor nutritional status
26,27
, so increased care in nutrition means 




ions to the intestinal 
lumen leads to thick mucus which can cause obstructions in the distal small intestine (meconium ileus 
for infants and distal intestinal obstructive system for older individuals) that can result in rupture and 
sepsis, and ultimately death. Inflammation is also a hallmark of the CF intestine, in which the 
defective mucus clearance allow abnormal bacterial colonization that alters the immune system 
behavior which, in turn, leads to an increase in mucus production
25
. 
 CF was initially described in 1938
28
 and, at the time, it was fatal in infancy. Currently, with 
symptomatic therapies such as digestive enzyme supplementation, mucolytic and hydrator therapies, 
airway clearance and frequent courses of antibiotics, the disease stopped being a childhood disease 
Figure 1.1 - Effects of CFTR functional deficiency in the airway epithelium. Reduced or absent Cl-/HCO3
- transport 
leads to hyper-absorption of Na+ reducing airway-surface liquid hydration, mucociliary clearance, and pH dysregulation, 
which leads to an increase in mucous viscosity and impairs innate immunity. This contributes to chronic inflammation 





and more than 50% of individuals with CF reach adulthood, as indicated being the median age of 
survival ~40 years
29
. However, this heavy therapeutic ‘load’ and the progressive loss of lung function 
still pose a high burden for the individuals with CF and the healthcare system
2
. Ultimately, all of these 
therapies work downstream of the disease and only treat the upcoming symptoms. If we want a more 
permanent solution for CF, it is essential to understand the CFTR gene and its role in the cell.  
  
1.2 CFTR 
1.2.1 Structure and Regulation of CFTR Protein 
 
 CFTR is a 1480-residue long membrane protein that is a member of the ATP-binding cassette 
(ABC) superfamily, although it is the only ABC protein that functions as an ion channel
30,31
. 
Moreover, unlike other ABC transporters that pump substrates against their electrochemical gradient, 
CFTR conducts anions down their electrochemical gradient
32
. Also, besides the sequence of two 
transmembrane domains (TMDs) that form the translocation pathway and two cytoplasmic nucleotide-
binding domains (NBDs) which hydrolyze ATP that all typical ABC transporter have, CFTR has an 
additional regulatory domain (RD) that must be phosphorylated to allow the open channel 
conformation
33,34
. Recently, the human CFTR structure was determined by cryo-EM
32
, which was 
important to understand the RD regulation and the ATP dependent channel gating. 
 The RD rests in a position that inhibits NBD dimerization and, thus, channel opening
32
. So, only 
upon phosphorylation of this domain by protein kinase A (PKA), ATP can bind to the NBDs, forming 
a dimer that changes the conformation of the TMDs opening the channel and allowing Cl
-
 efflux 
(Figure 1.3). Hydrolysis of ATP and release of inorganic phosphate causes the channel to close but it 
can rapidly open again upon the addition of another ATP molecule (Figure 1.3)
35
. At rest, the R region 
is kept dephosphorylated by phosphatase activity
36







Figure 1.2 - Structure of the human CFTR in the dephosphorylated, ATP free conformation. A. The domain 
organization of CFTR protein, starting in the N-terminus with the Lasso motif, followed by the TMD1 and NBD1, R domain 
towards the middle of the sequence, and TMD2 and NBD1 in the C-terminus. B. Ribbon diagram of the CFTR protein. Out 
is the outside of the cell and In is the cytoplasm. TMD1 and TMD2 are the transmembrane domains of CFTR, NBD1 and 
NBD2 the nucleotide binding domains and R is the regulatory domain. Numbers 1 to 12 identify the 12 transmembrane 
helices. The EM densities in red correspond to the unstructured regions of R domain and R domain association with NBD1. 
Dashed lines are unresolved regions. Retrieved from Liu, F. et al (2017).  
 
 CFTR biogenesis occurs at the endoplasmic reticulum (ER), which provides the first steps in the 
protein folding quality control
38
. Protein chaperones, such as calnexin, evaluate the folding state of 
CFTR and target misfolded proteins for ER associated degradation (ERAD) by the 26S 
proteasome
39,40
. Folded CFTR leaves the ER and goes to the Golgi network for final maturation before 
trafficking to the plasma membrane, by the endosome network
41
. The most common CFTR mutation 
F508del, a deletion in phenylalanine 508, affects protein trafficking. This mutation destabilizes CFTR 
structure and folding, making it a target for the ERAD pathway, with low amounts of mature proteins 
reaching the cell membrane
42
. As more mutations were discovered, causing different defects on the 






Figure 1.3 – Scheme of CFTR molecular mechanism. Grey lines are the lipid bilayer; the cytosolic part is at the bottom and the 
extracellular part at the top. The dark blue rectangle is TMD1 and the light blue is TMD2, the light green L shaped box is NBD2 
and the dark green is NBD1, and the purple oval is the R region. For CFTR activation, the R region is phosphorylated by PKA, 
allowing ATP binding to both NBDs. This changes TMDs conformation which allows the pore to open and the efflux of chloride 
and bicarbonate. Hydrolysis of ATP at the catalytically active site closes the channel, although it can be rapidly reopened by the 
addition of another ATP molecule. Retrieved from Cant, N. et al (2014). 
 
1.2.2 Functional Classification of CFTR Mutations and Theratypes 
  
The approximately 2200 described CFTR gene mutations consist in missense (39.6%), frameshift 
(15.6%), splicing (11.4%), and nonsense (8.3%) mutations; large (2.6%) and in-frame (2.0%) 
deletions or insertions; promoter mutations (0.7%); and non-pathological variants
1
. These mutations 
cause different cellular and molecular effects. Therefore, in order to facilitate the discovery of 
mutation-specific therapies, they can be grouped into seven classes according to the functional defect 
they elicit.  
 Class I mutations are mostly nonsense mutations, causing the production of truncated proteins 
and, often, nonsense-mediated mRNA decay. Class II mutations contribute to protein misfolding and 
retention at the ER with subsequent degradation, thus impairing protein traffic to the cell membrane. 
F508del mutation is included in this class. Class III mutations impair gating of the CFTR channel. 
Class IV mutations significantly diminish CFTR channel conductance. Class V mutations lead to a 
decrease in normal CFTR protein levels, usually due to alternative splicing that generates both normal 
and altered mRNA transcripts. Class VI mutations destabilize CFTR at the plasma membrane, either 
by increasing CFTR endocytosis or decreasing its recycling back to the membrane. Lastly, class VII 
mutations include large deletions and are called “non-rescuable” mutations because they cannot be 
pharmacologically rescued, and therefore there is the need to target alternative chloride channels or 

















 There are some CFTR modulator drugs that have been approved recently: VX-770 (Ivacaftor®) is 
a potentiator that is indicated for the treatment of class III mutations but has been shown to work in 
other mutations from class IV or V
43–45
; VX-809 (Lumacaftor®) is a corrector, which means that it 
assists in the correct protein folding and trafficking to the plasma membrane, which benefits 
individuals with the homozygous F508del mutation or other class II mutations and in the clinic it is 
combined with Ivacaftor® for an increase in benefit
46
; and VX-661 (Tezacaftor®), that corrects the 
same molecular defect as Lumacaftor® but in combination with Ivacaftor® it has been shown to have 
higher rescue effects for F508del homozygous individuals
47
. This last combination, known as 
Symkevi® in Europe, has also been approved for individuals with one F508del allele and one 




1.2.3 CFTR and Epithelial Differentiation  
 
 Besides its major role in chloride and bicarbonate secretion, fluid secretion and regulation of 
osmolarity, CFTR is also an important protein regarding epithelial differentiation. In the lung, its 
cellular distribution was found to change with the degree of differentiation of the epithelial cells, 
evolving from diffused expression (in nonpolarized cells) to a predominantly apical distribution (in 
differentiated and polarized cells) and it was observed that mutated CFTR impairs the proliferation of 
predominantly undifferentiated cell types (e.g. Club cells) and its expression is necessary for their 
Figure 1.4 – Summary of all seven CFTR functional mutation classes and respective therapeutic 
strategies. It is expected that each mutation from the same class responds to the same type of 
therapeutic strategy. However, class VII mutations cannot be rescued by any modulator and, thus, it is 






. Moreover, it was established that CF epithelia has impaired differentiation
51
. 
Experiments in epithelial differentiation with cell lines expressing WT-CFTR and F508del-CFTR 
have shown that the WT cells develop a larger transepithelial electrical resistance (a measure of 
epithelial tightness) than mutant cells
52
. This is also evidenced in the epithelia of tubular organs where 
protein interactions with CFTR are crucial in cell junction formation. Therefore, lack of CFTR 
compromises barrier function and normal function of epithelial tissue by affecting tight junctions and 
gap junctions formation
53,54
. In addition to differentiation, lack of CFTR also affects wound healing 
and normal airway epithelial regeneration. The delay in this process may even start fibrotic responses 
in the lung tissue
55
. In addition to its role in the epithelial differentiation process, CFTR is actually 
necessary to maintain the differentiated and polarized state of the differentiated cells.  Epithelial-
mesenchymal transition is a process whereby fully differentiated polarized epithelial cells transition 
into a mesenchymal phenotype, giving rise to apolar fibroblastoid cells, such as fibroblasts and 
myofibroblasts
56
.  Lack of CFTR activity and the inflammation processes in the lung linked with CF 
can induce Transforming Growth Factor – β1 – driven epithelial-mesenchymal transition, where the 
increase in proliferative cells causes an increased tissue remodeling and repair in the CF lung
57
. In 
summary, CFTR has a clear role in epithelial differentiation and epithelial tissue homeostasis that is 
yet poorly understood and should be further explored.  
 
1.3 Current Diagnosis Methods for CF 
 
 Usually, CF suspicion in an individual may arise from the presentation of typical clinical 
symptoms, having a CF case in the family or if there was a positive result in a newborn screening 
program. Then, the clinician needs to perform laboratory tests, classically sweat Cl
-
 concentration, 
nasal potential difference (NPD), genetic testing or other complementary methods (e.g. Cl
-
 current 




1.3.1 Sweat Chloride Concentration Test 
 
 The sweat test was first described in 1959 and it remains to this day the gold standard of CF 
diagnosis
59
. The standard sweat test (the Gibson and Cooke technique) needs to be performed with 
care and high skill, and consists in stimulating localized sweating by the iontophoresis of pilocarpine 
into the skin. Sweat is then collected on filter paper, gauze, or in microbore tubing
60
 over a controlled 
period of time. The test is considered positive when it presents a Cl
-
 concentration of more than 60 
mmol/L, and levels below 30 mmol/L are considered normal for all age groups
61,62
. Individuals with 
values in the intermediate range (30-60 mmol/L) probably have a CFTR mutation with a mild effect
63
. 
Also, some adults may have values in the intermediate range, so sweat Cl
-
 levels alone may be 
insufficient to diagnose CF in the older adolescent
64
. Nevertheless, it is still a widely used test for the 




1.3.2 Nasal Potential Difference (NPD) 
 
 The impairment of Cl
-
 conductance and 
subsequent Na
+
 hyper-absorption in individuals with 
CF can be detected by NPD measurements, which 
assess the voltage created by the movement of these 
ions through the epithelia. These measurements can be 
performed in the mucosa or the inferior turbinate by 
placing an exploring electrode on the respiratory 
epithelium and a reference electrode into the 
subcutaneous tissue of the forearm. Baseline potential 
difference (PD) is more negative in individuals with 
CF. Diagnostic is made by evaluating the bioelectrical 
profile change (in reference to the baseline) when 
amiloride (Amil), an ENaC inhibitor, is applied 
(becomes less negative in CF) following the addition 
of a Cl
-
-free solution and isoproterenol, that lowers the 
potential difference in an healthy individual and has  
little or no response in CF
65,66
 (see figure 1.5). Test 
results can be influenced by several factors such as 
recent viral infections, electrode position and the 
genotype, and are technically difficult, so only 
specialized centers perform this technique
67
.   
 
 
1.3.3 CFTR Genotyping 
 
 Although the CFTR gene was discovered in 1989, since then the diagnosis of CF cannot be based 
simply on gene sequencing and mutation analysis. Of the 2200 mutations already described, not all of 
them are yet characterized, meaning that some of them may not be “CF causing” or may not lead to a 
“classic CF” phenotype. Moreover, there are mutations that may not be confined to the gene but may 
be located in the promoter region or in other regulatory regions, so they would probably not be 
identified by the normal sequencing tests. Albeit two CF causing mutations should imply CF 
diagnosis, the diagnosis should be made regarding the clinical symptoms and laboratory tests, with the 




Figure 1.5 – Nasal potential difference 
measurement in (A) a healthy individual and (B) a 
person with classic CF. In a healthy individual the 
basal PD is negative, then rises (approaching zero) 
after the addition of Amil and decreases with the 
addition of a Cl—free solution and isoproterol. The 
individual with classic CF has a more negative 
baseline and has a faster rise in PD after the 
application of Amil. There is no alteration after the 
application of a Cl—free solution and isoproterol. 




1.3.4 Newborn Screening Programs 
 
 As newborn screening programs are being widely used, they have become the most common route 
of CF diagnosis, as opposed to the traditional way of analyzing the symptoms as they emerge. So far, 
many screening algorithms have already been developed
68
. The first step to neonatal screening is 
based on the immunoreactive trypsinogen assay (IRT), which is simple and inexpensive to perform on 
the newborn heel prick sample (Guthrie Test)
69
. In case of the CF newborns, the IRT levels remain 
elevated for weeks to months in both pancreatic sufficient and insufficient individuals, being repeated 
2 weeks after birth to increase the specificity
70
. These children proceed to further testing, which may 
include genetic testing for a panel of CFTR mutations that are more frequent in the population, as well 
as a sweat test
71
. Nevertheless, this screening is designed to pick up cases of classical CF, who will 
benefit from early therapy, and to exclude healthy carriers. There are sometimes equivocal diagnoses: 
infants that do not meet the diagnostic criteria for CF, that have a mutation that is not CF-causing or 
do not have clinical symptoms but, later in life, may develop organ changes that require intervention. 
The term CFTR-related metabolic disease was created to describe these cases in order to provide the 




1.3.5 Cl- current measurements using rectal biopsies in Ussing chambers 
 
 The measurement of Cl- ion secretion in human native colonic tissue have already been 
established as a robust ex vivo biomarker for the evaluation of CFTR function, which additionally can 
correlate with the CF individual genotype and clinical parameters such as sweat chloride 
concentration and fecal elastase E1 (FEE) levels
73–75
. To perform this test, a series of pharmacological 
stimuli are applied to directly and indirectly stimulate CFTR conductance and then the results can be 
divided into three groups (Figure 1.6).  
 At the start of the experiment, Amil is added to inhibit ENaC-generated Na
+
 currents. Then, 





) channels. This generates a driving force for Cl
-
 secretion through 
CFTR and elicits lumen-positive responses in tissues from individuals with CF and lumen-negative in 
non-CF tissues (Figure 1.6, first peak). Thus, when CCH is applied a second time, now in the presence 
of indomethacin (Indo) to inhibit endogenous cAMP production, there is no cAMP and CFTR-
mediated Cl
-
 secretion, so we get lumen-positive responses from K
+
 secretion (Figure 1.6, second 
peak). Shortly after, when 3-isobutyl-1-methylxantine (IBMX) and Forskolin (Fsk) are added to elicit 
cAMP-dependent CFTR-mediated Cl
- 
secretion, lumen-negative responses are observed in non-CF 
individuals (Figure 1.6A, third peak) and “non-classic CF” individuals (Figure 1.6B, third peak) but 
no response is observed from the “classic CF” subgroup (Figure 1.6C). Lastly, still in the presence of 
the last reagents, CCH stimulation creates three different responses on the subgroups: monophasic 
lumen-negative in tissues from “normal” individuals (Figure 1.6A, fourth peak); biphasic responses in 
the “non-classic CF” individuals (Figure 1.6B, fourth peak); and monophasic lumen-positive in tissues 






Figure 1.6 – Three possible micro-Ussing chamber readouts for the assessment of CFTR function and the distinction 
between subtypes of individuals. A This is the normal CFTR function readout, with lumen-negative response to carbachol 
(CCH) and lumen-positive response in the presence of indomethacin (Indo) and amiloride (Amil). There is CFTR-mediated Cl- 
secretion after the stimulation with IBMX/Fsk and CCH on top, as evidenced by the lumen-negative responses. B Two lumen-
positive responses to CCH (with and without Indo) followed by a smaller (compared to the normal) lumen-negative response to 
IBMX/Fsk. When CCH is added, there is a biphasic response consisting in a lumen positive response due to K+ secretion followed 
by a lumen-negative response due to CFTR activity and Cl- transport. C This is a classic CF readout, with three lumen-positive 
responses to CCH due to lack of CFTR activity and no response to IBMX/Fsk. Adapted from Sousa, M. et al (2012). 
 
1.4 CF Personalized Therapies 
 
 In recent years, the emergence of CF modulator drugs gave a chance of therapy to individuals 
with CF. Nevertheless, the CF modulators are only approved for certain mutations. Since mutations 
from the same class may benefit from the same therapies and there are factors other than CFTR 
genotype that influence drug response, individuals with CFTR genotypes other than the approved ones 
can benefit from the same CFTR modulators and not all individuals with CF will benefit from the 
approved therapies. Thus, over the years, in vitro models have been developed to predict each 
individual’s drug response in a precision medicine approach. In this way,  care for individuals with CF 
can be done with a more personalized medicine approach, where one drug does not fit all, but there 
may be a right drug for each individual with CF. 
  
1.4.1 Primary Human Bronchial/Nasal Epithelial Cells 
 
 Recently, primary cultures of human bronchial epithelial cells (HBEC) and human nasal epithelial 
cells (HNEC) have been developed to replicate in vitro the physiological and pathophysiological 
conditions occurring in vivo, as closely as possible. These cells can be collected from individuals with 
CF and non-CF controls and, with the appropriated culturing conditions, can be differentiated in to the 
main cell types present in the airways and acquire the normal in vivo morphology and key cellular and 
physiological processes
76
. Both models can be used for drug response assessment in individuals with 
CF in a personalized medicine approach by using, for instance, electrophysiological approaches in 







 HNECs are easily accessible by nasal brushings (which are less invasive than rectal biopsies) and 
are a good model to study CFTR ex vivo. Thus, recently, this allowed using differentiated HNECs to 
form spheroids in vitro that maintain the normal tissue morphology and differentiated state (ciliated 
cells are present and there is mucus production), and replicate better the physiological transport events 
than a cell monolayer
79,80
. There are nasospheroids developed that maintain a “lumen out” 
configuration (cilia are in contact with the culture medium) in which there is an increased accessibility 
of the drugs (e.g. VX-770) to the luminal side and an increase in CFTR function causes the organoid 
to shrink
79
. Conversely, there are also nasospheroids that retain a “lumen in” configuration and, in this 
case, CFTR rescue can be assessed by the level of spheroid swelling
80
. Both of these models can be 
used to study pharmacological manipulation of CFTR and drug rescue in a personalized medicine 
approach. Nevertheless, these kinds of 3D models have their limitations, such as a big variability in 
spheroid diameter and spheroid swelling that difficult analysis and quantification, and a short lifetime 
in culture.  
 
1.4.3 3D Intestinal Organoids 
 
 Another model recently developed is the use of intestinal 3D organoids, which are formed from 
intestinal crypts, to assess CFTR function
81
. The intestinal crypts can be isolated from rectal biopsy 
tissue and contain at their base LGR5+ stem cells
82
 that allow the generation of the intestinal 
organoids (Figure 1.7).  
 
 
Figure 1.7 – Crypt structure, cell composition and distribution in the colon crypts. Structure of the colonic crypts seen by a 
scanning electron micrograph (left panel). LGR5+ stem cells at the crypt base generate rapidly proliferating transit-amplifying 
cells in the lower half of the crypt (middle panel). These cells subsequently differentiate into the mature lineages of the epithelium 
(Absorptive enterocytes, goblet cells, Tuft cells and enteroendocrine cells) as shown in the lineage tree (right panel). Adapted 
from Barker, Nick (2013). 
12 
 
These organoids are made from cells expressing high levels of CFTR and are a good tool for the 
indirect assessment of CFTR function using the forskolin-induced swelling assay (FIS)
81
. In this assay 
the organoids swell in presence of forskolin, a compound that activates the adenylyl cyclase enzyme 





 ions follow through the paracellular space resulting in fluid secretion to the lumen
83
. 
This swelling can be observed by using confocal microscopy and depends uniquely on CFTR activity, 
as shown by the use of CFTR inhibitors and modulators (Figure 1.8). Moreover, this assay can be used 
for the analysis of CFTR rescue after the use of modulators and even for drug development 
purposes
84–87
. These organoids can be expanded indefinitely in culture and can be selected to be 
roughly the same size, which are clear advantages when compared to the nasospheroids, and provide a 





1.4.4 2D Intestinal Monolayers 
 
 There is a disadvantage in using the FIS assay with the 3D organoids. In the case of WT and 
residual function genotypes, there is pre-swelling of the organoids which may undervalue the swelling 
of those organoids in response to CFTR modulators. Thus, one attractive alternative would be to split 
the 3D organoids and seed the cells in porous membrane supports to generate a monolayer of 
undifferentiated intestinal epithelial cells (Figure 1.9) that maintain CFTR activity and can be further 
differentiated into the several differentiated cell types found in the colon
89
 (See Figure 1.7). Thus, this 
apparently versatile model could potentially be used to evaluate ion transport through CFTR or CFTR 
functional rescue by CFTR modulators in a personalized medicine approach using, for instance, 
Figure 1.8 – Forskolin-induced swelling assay. At t=60 a visible swelling can be observed in CF individual (F508del 
homozygous) derived intestinal organoids treated with VX-809, VX-770 and even greater with the combination (VX-809/VX-
770) when compared with the control. Using a CFTR inhibitor we can see no visible swelling from the organoids treated with the 
combination therapy, meaning that the swelling observed is CFTR-dependent. On the far right is represented the swelling of non-




micro-Ussing chambers, as it is currently being done with the HBECs/HNECs. In these assays, ion 
flow can be measured directly as opposed to fluid secretion like in the 3D-organoids. Moreover, this 
model could be used to study intestinal epithelial differentiation and its effect on CFTR and other 
related ion channels, and how mutated CFTR can affect this differentiation process. 
 
 
Figure 1.9 – Histological section of the 2D intestinal monolayers derived from 3D intestinal organoids.  A monolayer of cells 
can be generated both with WT cells and CF patient derived cells and with differentiation increase in size, present villus-like 
structures and test positive for mucins and other glycoproteins with the Alcian Blue/Periodic Acid-Schiff staining. Adapted from 
















The main goals of this MSc project were: 
1) To characterize the novel 2D-intestinal cellular system by assessing: 
 
a. The expression levels of plasma membrane (PM) proteins and ion channels present in the 
native tissue which are essential for Cl
- 
secretion;  
b. The differentiation status and progress of the 2D-intestinal epithelial monolayers by 
differentiation and proliferation markers under differentiation and non- differentiation 
conditions.  
 
2) To compare CFTR function in native tissues and primary cultures derived from individuals 
with CF and non-CF controls by: 
 
a. Ussing chamber measurements of CFTR-mediated Cl- secretion in fresh rectal biopsies; 
b. Forskolin-induced swelling (FIS) assay of intestinal 3D-organoids derived from rectal 
biopsies; 
c. Ussing chamber measurements of 2D-intestinal monolayers. 
 
3) To establish correlations between: 
 
a. Values obtained in 2a, 2b and 2c for the same individuals as well as with other CF 
phenotypes from these individuals, in order to assess if 2D-intestinal monolayers 
recapitulate the properties of the more established models in predicting disease severity so 
as to validate them as good personalized cell models for CFTR function and thus for CF 
diagnosis/prognosis; 
b. Values obtained in 2b and 2c for the same individuals to determine whether 2D-intestinal 
monolayers recapitulate the CFTR modulator drugs found in 3D-organoids and thus 










3. Materials and Methods 
 
 Experiments described in this thesis were performed at the lab of Professor Dr. Margarida 
Amaral’s group (FunGP, BioISI, Faculty of Sciences, University of Lisboa, Portugal) over the work 
period of one year. 
 
3.1 Cell Culture 
 
 All cells were grown at 37 ºC in a 5% CO2 and 95% air-humidified water saturated atmosphere. 
All cell culture was performed according to standard conditions. 
3.1.1 Culture conditions of the human intestinal organoids 
 
 The crypts were isolated from human rectal biopsies and intestinal organoids were cultured as 
previously described
90
 by Beekman’s lab, Utrecht, The Netherlands. Briefly, biopsies were washed 
with PBS (Corning, USA) and then treated with 10 mM EDTA (Invitrogen, USA) in PBS for 90 min 
at 4ºC with continuous rocking. Later, the crypts containing the LGR5
+ 
positive stem cells were 
disrupted from the tissue by vigorously washing with PBS and saving the supernatant. Supernatant 
was centrifuged (230g, 5 min, 4 ºC), and pelleted crypts were re-suspended in 50% (v/v) Matrigel 
Matrix (Corning, USA), diluted in complete culture medium consisting of 20% (v/v) F12
ghp
, 2% (v/v) 
B27 (Invitrogen, USA), 1.25 mM N-acetylcysteine (Sigma-Aldrich, USA), 50 ng/mL mouse 
epidermal growth factor (Invitrogen, USA), 50% (v/v) Wnt-3a-conditioned medium (lab-made), 10% 
(v/v) Noggin-conditioned medium (lab-made), 30% (v/v) R-spondin-conditioned medium (lab-made), 
10 mM nicotinamide (Sigma-Aldrich, USA), 50 nM TGF-β inhibitor A83-01 (Tocris Bioscience, 
Germany), 10 µM P38 MAPK inhibitor SB202190 (Sigma-Aldrich, USA) and 0.2% Primocin 
antibiotic (InvivoGen, USA). Crypts were seeded in matrigel with a density of around 10-30 crypts 
per 10 µL matrigel droplet. The matrigel was polymerized for approximately 15 min at 37 ºC 5% CO2 
and the complete culture medium was then added. 0.1% Gentamicin (Sigma-Aldrich, USA) was added 
to culture medium for the first week of culture since passage 0 is more susceptible to contamination. 
Medium was refreshed every 2-3 days. Crypts rapidly close and bud into intestinal organoids after 7-
10 days after which they were passaged (Figure 3.1). Culture medium was refreshed every 2-3 days 




Figure 3.1 – Schematic representation of organoid generation from plated intestinal crypts from rectal biopsies. The 
plated crypts in matrigel matrix will start to close and proliferate. After 7-10 days they can be mechanically disrupted into 
smaller individual organoids that are further expanded. Retrieved from Dekkers, van der Ent & Beekman (2013). 
 
3.1.2 Culture conditions of the 2D intestinal monolayers 
 
 The generation of the 2D intestinal epithelial cell monolayer in porous membrane filters was 
performed as already described by the Beekman’s lab, Utrecht, The Netherlands
89
. The matrigel 
droplets containing the 3D organoids are disrupted and the organoids are pooled in F12
ghp
 and spun 
down (230g, 5 min, 4ºC), after which the medium is removed. To the organoid pellet 500-700 µL of 
TrypLE Express 1X (Gibco, USA) is added and it is re-suspended with an F12 pre-coated p200 tip. 
The cells are incubated twice at 37 ºC for 2 min and disrupted with an F12 pre-coated tip after each 
incubation. The percentage of single cells is then checked (at least 90%) and the tube is put directly on 
ice and inactivated with the TrypLE inactivation solution (10% FBS in F12
ghp
). The cells are 
centrifuged (282g, 5 min, 4 ºC, medium removed) and pooled, after which they are counted in a 
Neubauer counting chamber (the amount needed is 250,000 cells per filter). The cells are re-
suspended in the first day culture medium (complete organoid medium (see section 3.1.1)) with the 
addition of 10 µM ROCK inhibitor Y-27632 (Selleck Chemicals, USA) and transferred to the apical 
side of Transwell® 6.5mm polyester 0.4 µm pore membrane inserts (Corning, USA). 600 µL of 
culture medium is added in the basolateral side. The next day, the filters are refreshed with complete 
organoid culture medium without ROCK inhibitor. On the fifth day, TEER is measured with a 
Millicell-ERS voltmeter with a chopstick electrode (Millipore, USA) and it should be at least 
100Ωxcm
2
. If so, Ussing chamber experiments can be performed on the undifferentiated monolayer 
(see section 3.2.2) or the filters can be switched to the differentiation medium. To differentiate the 
intestinal epithelial monolayer, filters are refreshed with the differentiation medium, which is the 
organoid culture medium without the Wnt-3a-conditioned medium, nicotinamide and the P38 MAPK 
inhibitor SB202190. Medium is refreshed every 2 days until the TEER values are, at least, 800Ωxcm
2
, 
making the filters suitable for Ussing chamber experiments and indicating that a tighter cell 
monolayer is formed.  
 To test for the CFTR functional rescue, the undifferentiated monolayers are treated with CFTR 
correctors (3 µM VX-661 (Selleck Chemicals, USA) (dissolved in DMSO) or 0.05% DMSO (control 




3.2 Functional CFTR analysis 
 
3.2.1 Measurement of CFTR Mediated Cl- Secretion in Rectal Biopsies 
 
 Biopsies from individuals with CF were obtained in Hospital de Dona Estefânia (Lisbon, 
Portugal), Hospital Santa Maria (Lisbon, Portugal), Centro Hospitalar e Universitário de Coimbra and 
Motol University Hospital (Prague, Czech Republic). The colon preparation was performed by 
applying an enema of saline solution and superficial rectal mucosa biopsies (2.8 mm in diameter) were 
obtained by rectoscopy and forceps biopsy. The tissues were mounted in Ussing chamber inserts 
under a stereomicroscope using dissection forceps. The inserts were the fixed between the two half 
cells of the Micro-Ussing chambers, separating the apical from the basolateral bath solutions. 
 Transepithelial measurements were performed under open-circuit conditions in micro-Ussing 
chambers as described previously
73,75
. The tissue was perfused continuously with Ringer buffer (NaCl 
145 mM, KH2PO4 0.4 mM, K2HPO4•3H20 1.6 mM, D-glucose 5 mM, MgCl2•6H20 1 mM, Ca-
gluconate•H20 1.3 mM, pH 7.4, 280 mOsm/Kg) until a baseline is achieved, followed by the 
experimental solutions. Voltage (Vte) values were recorded at all times with Power Lab software (AD 
Instruments Inc., New Zealand). Values for Vte were referred to the basolateral side of the epithelium 
and resistance (Rte) was determined by applying short intermittent pulses (0.5 µA/s), measuring 
pulsated deviations in Vte and accounting for the area of the inserts. An empty insert was previously 
recorded to correct the measured values. Equivalent short-circuit currents (Ieq-sc) were calculated using 
Ohm’s law (Ieq-sc = Vte/ Rte).  
 After a baseline is achieved, amiloride (Amil, 20 µM, apical) (Sigma-Aldrich, USA) was applied 
to block electrogenic Na
+
 absorption through ENaC. Next, carbachol (CCH, 100 µM, basolateral) 





ion channels, eliciting a driving force for Cl
-
 secretion. Indomethacin 
(Indo, 10 µM, basolateral) (Sigma-Aldrich) was then applied for 20 min to inhibit prostaglandin 
production and abolish endogenous cAMP production and thus CFTR-mediated Cl
- 
secretion. After 
this, CCH was applied again in the presence of Indo to induce only K
+
 secretion. Following a new 
washout with Indo, an IBMX/Forskolin (IBMX/Fsk, 100 µM/2 µM, basolateral) (Sigma-Aldrich, 
USA) solution is added (in the presence of Indo) to stimulate cAMP production through the activation 
of the adenylyl cyclase enzyme and inhibit cAMP degradation through phosphodiesterase, thus 
activating CFTR-mediated Cl
-
 secretion. Lastly, CCH was added on top of the previous solutions for a 
cholinergic co-activation of CFTR. 
 
3.2.2 Measurement of CFTR Mediated Cl- Secretion in 2D Intestinal Monolayers 
 
 Intestinal epithelial 2D-monolayers grown in porous membrane supports (see section 2.1.2) were 
mounted between two round half-inserts with central open areas of 0.33 cm
2
 and fixed in the middle 
of the two-half cells of the micro-Ussing chambers. To assess CFTR basal function, transepithelial 
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measurements were performed as described previously (see Section 3.2.1). After the addition of the 
solution containing Indo, IBMX, Fsk and CCH (10 µM, 100 µM, 2µM and 100 µM, basolateral), a 
solution of CFTR-specific inhibitor 172 (CFTRinh-172, 30 µM, apical) (Cystic Fibrosis Foundation 
Therapeutics, USA) was applied to inhibit CFTR-mediated Cl
- 
secretion.  
 To evaluate CFTR functional rescue with the correctors and potentiators, the 2D monolayers were 
treated as described above (see section 3.2.1) and also mounted on the micro-Ussing chambers. 
Briefly, the cells were bathed in Ringer solution on both sides and, after a baseline is achieved, a 
solution of Amil (20µM, apical) was applied to block ENaC, as before. Next, IBMX/Fsk (100µM, 
0.8µM, apical) was added to stimulate CFTR-mediated Cl
-
 secretion. To assess if it is possible to 
further potentiate CFTR activity, a solution of VX-770 (3µM, apical) (Selleck Chemicals, USA) was 
added. Lastly, CFTRinh-172 (30 µM, apical) was added to assess the specificity of the cAMP-
dependent activation. Three replicates of both conditions (VX-661 and DMSO) were tested and CFTR 
functional rescue was assessed by comparison of ΔIsc-IBMX/Fsk values between control and treatment. 
 
3.2.3 Forskolin-induced swelling assay 
 
 The FIS assay was performed as previously described
81
. The organoids from each individual with 
CF were seeded in matrigel in a pre-warmed 96-well culture plate and treated with the corrector VX-
661 (3 µM) for 24h. Before the assay, serial dilutions of 0.02, 0.128, 0.8 and 5 µM solutions of Fsk 
alone or in combination with VX-770 (3 µM) were prepared. After the 24h incubation period, calcein 
green (3µM) (Invitrogen, USA) was added to the organoids and live cell imaging was carried out in a 
confocal microscope (Leica TCS SP8 Falcon, Leica Microsystems, Germany), at 37 ºC 5% CO2 and 
two sets of images (fluorescence and bright field) were taken for 60 min with 10 min intervals (7 time 
points in total). 
 Using the set of fluorescence images, the organoid swelling was quantified using Cell Profiler 
software (Broad Institute’s Imaging Platform, USA) and a pipeline developed by a lab member (Hugo 
Botelho). The results were plotted using Graph Pad Prism v6 software, in which the quantification of 
the surface area increase relative to t = 0 (normalized area, Figure 3.2) at different Fsk concentrations 
per treatment was averaged from two independent wells per assay. The results were then expressed as 
the absolute area under the curve (AUC) calculated from the normalized area (baseline = 100%, t = 60 
min), averaged from a minimum of n=3 independent assays. Control organoids (CF114, 
F508del/S1251N) were also plated in each independent assay and the concentration of Fsk in which 
they respond (seen by the increase in AUC) to the potentiator VX-770, was the concentration used to 
evaluate treatment response and CFTR functional rescue. So, CFTR rescue was assessed by 
comparison of average AUC values between the control column (Fsk only) and the treatment columns 
(Fsk + VX-770, Fsk + VX-661, Fsk + VX-661/VX-770) for [Fsk] = 0.8 µM. Comparison with the 




3.3 Expression Analysis 
 
3.3.1 Gene Expression Analysis 
3.3.1.1 RNA Purification 
 
 When the 3D-organoids were confluent and the filters reached the appropriate resistance, the 
RNA was collected from the cells and purified using the NZY Total RNA Isolation Kit (Nzytech, 
USA), according to manufacturer’s instructions. RNA concentrations, as well as sample purity, were 
evaluated using a Nanodrop ND1000. 
 
3.3.1.2 cDNA Synthesis 
 
 In order to perform RT-PCR assays, purified RNA was used to generate cDNA. This was 
performed with NZY M-MuLV Reverse Transcriptase (Nzytech, MB08301), according to 
manufacturer’s instructions. Briefly, to 1µg of purified RNA a mix of 0.2 µg of random hexamers and 
a 0.5 mM mix of dNTPs (mix of dATP, dGTP, dCTP and dTTP, Nzytech, MB08701) were added. 
Next, the tubes were heated to 65ºC for 5 min and rapidly put on ice. Finally, 100 U of the reverse 
transcriptase, RNase inhibitor (Nzytech, MB08402) and 1x reaction buffer were added, and the 
reaction was performed in a thermocycler with the following conditions: 10 min at 25ºC, 50 min at 




 The reagents of the PCR reaction are described in table 3.1 and the reaction was carried out as 
described in table 3.2. The reaction conditions were optimized for each primer used (see table 3.3). 
 After the reaction, the PCR products were analyzed in a 2% agarose (SeaKem LE Agarose, 
Lonza) gel using a RedSafe nucleic acid staining solution (Intron Biotechnology). For size 







Table 3.1 – Reagents used in the PCR reactions. 
Reagent Volume (µL) 
H20 until 25  
Buffer 10x 2.5 
MgCl2 (50 mM) 0.75 










cDNA (50 ng/µL) 1 
 
Table 3.2 – PCR programme used in the PCR reactions. 
Step Duration (min) Temperature (ºC) 
Initial Denaturation 5 95 
Cycle - Denaturation 1 95 
Cycle - Annealing 1 60/64 
Cycle - Elongation 1 72 
Final Elongation 5 72 
Total of 40 Cycles 
 
Table 3.3 – Primer sequences used for each gene studied in this work and annealing temperature of each primer. 
Gene Forward Sequence 5'>3' Reverse Sequence 5'>3' Temperature 
of annealing 
(ºC) 
CK18 CACAGTCTGCTGAGGTTGGA GAGCTGCTCCATCTGTAGGG 60  
CFTR GCAAACTTGACTGAACTGGA GGTGCTGGTGATAATCACTG 60 
DRA GAGAGCACAGGAGGCAAAAC CAGCAAACTGCATCAGCATT 60 
IK CGGGAACAAGTGAACTCCAT ACTGGGGAAAGTAGCCTGGT 60 
BK TAAGGACACCAGGAGGGTTG GCTCTGAGACTTGGGGAGTG 64 
E-cad CGAGAGCTACACGTTCACGG GGGTGTCGAGGGAAAAATAGG 64 
NKCC1 CCAGAATTTGGTGGTGCAATT TTTGGGTATGGCTGACTGAGG 60 
LGR5 GAATCCCCTGCCCAGTCTC ATTGAAGGCTTCGCAAATTCT 64 
ENaC TCCTACCCTCGTCCCTACCT CCAGGAAGGAGAAAACCACA 64 
SLC26A9 AGGTCACAGAGCCTCAGGAA CTGAGCCTCAACTCCAGGTC 64 





3.3.2 Western Blot 
 
 When the 3D-intestinal organoids were confluent, matrigel was re-suspended and the organoids 
were pooled in F12
ghp
 and centrifuged (230g, 5 min, 4ºC). The medium was removed and cold PBS 
was added to re-suspend the pellet, following another spin down (230g, 5 min, 4ºC). In order to obtain 
the lysates, the appropriate amount of lysis buffer (31.25 mM Tris HCl (Sigma-Aldrich, USA) pH 6.8; 
sodium dodecyl sulfate (SDS) 1.5% (v/v) (Gibco, USA); glycerol 5% (v/v) (Sigma-Aldrich, USA); 
bromophenol blue 0.02% (w/v) (Sigma-Aldrich, USA); dithiotreitol 50 mM (Sigma-Aldrich, USA); 
1% Protease inhibitor cocktail (Roche, Germany)) was added to the pellet. Also, benzonase (Sigma-
Aldrich, E1014) 25U/ml, in the presence of 3 mM MgCl2, was added to shear the DNA. For the 
confluent 2D-monolayers, filters were washed with cold PBS on the apical side and 40 µL of lysis 
buffer was added to the apical side. The surface of the filters was scraped to collect protein lysates. 
 Both samples were then separated by SDS-PAGE using a 7% (w/v) separating gel (Tris-HCl 375 
mM pH 8.8; acrylamide:bisacrylamide 7% (v/v) (Bio-Rad, USA); glycerol 0.1% (v/v); SDS 0.1% 
(v/v); ammonium persulfate (APS) 0.075% (v/v) (Bio-Rad, USA); tetramethylethylenediamine 
(TEMED) 0.06% (v/v) (Sigma-Aldrich, USA)) and a 4% stacking gel (Tris-HCL 125 mM pH 6.8; 
acrylamide:bisacrylamide 4% (v/v); SDS 0.1% (v/v); APS 0.075% (v/v); TEMED 0.08% (v/v)). The 
electrophoresis was run on a Tris-Glycine-SDS buffer (Bio-Rad, USA) at 60-100V until the migration 
front reached the end of the gel. The separating gel was transferred to a polivinylidene difluoride 
membrane (Merck Millipore, USA) using a Tris-Glycine buffer (Bio-Rad, USA), at 400 mV for 
1h30min. The membranes (except for CFTR analysis) were blocked for, at least 30 min with 5% (w/v) 
skimmed milk (Nestlé, Molico, Switzerland) in PBS supplemented with Tween 20 0.1% (v/v) (PBS-
T) and then incubated overnight at 4ºC with primary antibodies (Table 3.4) diluted in 5% milk in 
PBS-T. After washing 3 times for 10 min each with PBS-T, the membranes were incubated with the 
horseradish peroxidase (HRP)-conjugated secondary antibody (Table 3.5) 1h at room temperature. For 
the CFTR analysis, the previous steps were made using TBS-T and a 1% (w/v) skimmed milk in TBS-
T. To reveal the bands, a chemiluminescent reaction was made with a mixture of 
peroxide:luminol/enhancer solution 1:1 (Bio-Rad, USA) and it was detected through a Chemidoc XRS 
plus analyzer (Bio-Rad, USA). Quantification of the intensity of the bands was performed using the 
ImageLab software (Bio-Rad, USA).  
 
      Table 3.4 – Primary antibodies used in this work. 
Primary Antibodies 
Target Dilution Host Company Reference 
CFTR 1:500 Mouse CFF 596 
N-cadherin 1:500 Mouse BD Biosciences 610920 
E-cadherin 1:5000 Mouse BD Transduction Lab 610181 
Cytokeratin-18 1:1000 Mouse Santa Cruz sc-32329 





 ATPase α 1:1000 Mouse Santa Cruz sc-48345 
GAPDH 1:10000 Mouse Abcam ab8245 
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   Table 3.5 – Secondary antibodies used in this work. 
Secondary Antibodies 
Antibody Target Dilution Host Company Reference 
(H+L)-HRP Conjugate Mouse IgG 1:3000 Goat Bio-Rad 170-6515 
(H+L)-HRP Conjugate Rabbit IgG 1:3000 Goat Bio-Rad 170-6516 
 
3.4 Statistical Analyses 
 
 Statistical differences were calculated using Student’s t-test or analysis of variance (ANOVA) as 
suitable. Data are expressed as mean ± standard deviation (SD). Pearson coefficients (r, for normal 
samples) and Spearman coefficients (ρ, for not normal samples) were used to find correlations and partial 
correlations amongst patients’ clinical data and laboratory assessed CFTR function parameters. P-values 



















4. Results and Discussion 
 
4.1 Description of Phenotypes of Individuals with CF 
 
 For this project, samples were collected from individuals with CF at several centers, namely 
individuals CFL54/59/61/65 are from Motol University Hospital (Prague, Czech Republic), CFL70 is 
from Hospital de Dona Estefânia (Lisboa, Portugal), CFL75 is from Centro Hospitalar e Universitário de 
Coimbra (Coimbra, Portugal) and CFL80 is from Hospital de Santa Maria (Lisboa, Portugal). An 
overview of laboratory, clinical data and biologic material analyzed from these individuals with CF is 
presented in table 4.1.  
 
Table 4.1 – Overview of data from individuals with CF: Individual’s codes; CFTR genotypes; sex (M = male, F = female); age 
at study; age at diagnosis (NBS = newborn screening); fecal elastase E1 values (FEE, µg/g stool); exocrine pancreatic function 
(PS = pancreatic sufficient, PI = pancreatic insufficient); forced expiratory volume in 1 sec in percentage predicted (FEV1, %) and 
sweat [Cl-] (mmol/L) at time of samples collection; samples analyzed (rectal biopsies (B), intestinal organoids (3D), and 2D 



















CFL54 F508del/R347P F 18 1 351.0 PS 64 84.6 B, 3D, 2D 
CFL59 F508del/S955P M 7 0 (NBS) 500.0 PS 95 56.5 B, 3D, 2D 
CFL61 F508del/G542X M 8 0 (NBS) 1.0 PI 95 82.7 B, 2D 
CFL65 F508del/F508del M 13 2 1.0 PI 89 117.0 B, 3D, 2D 
CFL70 F508del/A561E M 1 0 30 PI 101 112 B, 3D, 2D 
CFL75 F508del/R334W F 8 0 500 PS 124 91.0 B, 3D, 2D 
CFL80 F508del/F508del F 13 2 1 PI 61 125.0 B, 3D, 2D 
 
 
4.2 Characterization of the 2D Intestinal Monolayers 
 
In order to understand whether this novel cellular model can be used for further functional studies in 
addition or replacement of the models currently used to analyze CFTR function (sections 4.3 and 4.4), a 
series of gene and protein expression analysis were made by using RT-PCR and WB. Since the 2D-
monolayers can be cultured in both non-differentiating and differentiating conditions, the objective was to 
understand if the same ion channels were expressed in the 2D-monolayers grown under these two different 
conditions/ differentiation states and to compare their expression patterns with those of the 3D-intestinal 
organoid model already in use. Another goal was to compare CFTR gene and protein levels among the 




4.2.1 Gene Expression Analysis Comparison Among Models  
 
 As mentioned before, ENaC function is related with CFTR and, in case of CFTR functional loss, 
ENaC is upregulated in the airways, which leads to Na
+
 hyper-absorption. ENaC consists in three subunits 
(α, β e γ) which assemble in a 1:1:1 heterotrimers
91
. In the colon, ENaC is upregulated and the insertion of 
its β-subunit promotes ENaC activity
92
. Therefore, for these analyses ENaC β-subunit was targeted. 




 entry across the basolateral 






 cotransporter 1 (NKCC1) and, 
ultimately, the rate of basolateral Cl
-







 channels is also necessary for Cl
-
 secretion. Ion flux studies under voltage clamp conditions 
show that K
+
 channels localized on the basolateral membranes provide the driving force for active Cl
-
 
secretion in trachea and colon
94
. The intermediate conductance (IK) K
+
 channel (encoded by the KCNN4 




 channel located in both apical and basolateral membranes of the human 
colonic epithelial cells. The large conductance (BK) K+ channel is also a Ca2+-activated K+ channel but is 
located mainly in the apical membrane of epithelial cells
95,96
. Solute-linked carrier(SLC)26A9 is a cell 
membrane transporter that interacts with CFTR by its STAS domain
97
, and its presence results in an 
increased agonist-stimulated anion conductance in airway cells in a CFTR-dependent way
98
. This member 
of the SLC family has also been reported as a strong modifier gene in CF intestinal and pancreatic 
disease
99,100




 exchanger in epithelial cells and is potently activated by 
CFTR
101
. These channels were also analyzed by RT-PCR.  Finally, to check for the differentiation status 
of the cells, LGR5 was used in addition to CK18 and E-cad. LGR5 is a stem cell marker that is found in 
the crypt base columnar cells but not in the more differentiated cell types of the colon
82
, making it a good 
marker to assess the differentiation of the 2D monolayers. 
 Firstly, in order to characterize the presence of CFTR, CFTR-related ion channels, other channels 
that are essential for Cl
-
 secretion and some differentiation markers, gene expression analyses were made 
using the fresh tissue (rectal biopsies), 3D intestinal organoids and 2D intestinal monolayers (both 




Figure 4.1 - Gene expression analysis of CFTR and related membrane proteins and ion channels, and differentiation 
markers. Gene expression was analyzed for a WT donor: A - rectal biopsy; B – 3D-organoids; C - Undifferentiated 2D-
monolayers; D – Differentiated 2D-monolayers. The expression of Cl- channels and proteins essential for Cl- secretion, such as 
CFTR, NKCC1, IK, BK and SLC26A9 were analyzed. ENaC expression was also analyzed as well as DRA, which is related with 
HCO3
- secretion. Differentiation markers like LGR5, E-cad and CK18 were analyzed. GAPDH levels were used as a control. NC – 
Negative Control.  
 
 By comparison of the gene expression results from the fresh biopsies and the 3D-organoids, we 
can observe that all genes analyzed are expressed in both samples. Since the biopsies are composed by 
several cell types of the mucosa (stem cells of the crypts and differentiated cells of the villi) and the 3D-
organoids are composed by several crypt cells, it was expected that the gene expression on both samples 
would be different. However, the results show that for example CFTR and NKCC1 are both expressed in 
the biopsies and in the 3D-organoids, as well as LGR5, which is in agreement with the existence of stem 
crypt cells in the native tissue. ENaC seems to be very low expressed in both models, which is in 
agreement with the lack of amiloride-sensitive currents observed in the WT rectal biopsies analysis in the 
Ussing chamber (see section 4.2.3). Both IK and BK channels are expressed in the biopsies and 3D-
organoids, which are crucial for the CFTR function analysis in the rectal biopsies, generating CCH-
stimulated positive currents in individuals with CF (see section 4.4). Moreover, SLC26A9 is expressed, 
making the 3D organoids a possible tool for the analysis of this alternative Cl
-
 transporter.  Analyzing the 
undifferentiated intestinal 2D-monolayers, we can observe that the genes that are expressed are the same 
as those expressed in the 3D organoids. This is expected since these monolayers are derived from the 
individual’s 3D organoids. In this case, the change in culture conditions to permeable membrane supports 
does not alter gene expression. In the differentiated intestinal 2D-monolayers, however, there is one 
striking difference which is the loss of the stem cell marker of the crypt-base cells LGR5. This result 
indicates that the differentiation process has occurred as expected and that the stem cells present in the 
fresh biopsies, 3D intestinal organoids and undifferentiated 2D-monolayers are no longer present in the 
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differentiated intestinal 2D-monolayers. The potassium channels IK and BK are still expressed in both 
monolayers, so there should be K
+
 secretion in both undifferentiated and differentiated conditions. As 
observed in the rectal biopsies and 3D-organoids, ENaC expression is still very low and CFTR and 
NKCC1 genes are still expressed in both monolayers. Nevertheless, CFTR, CK18 and E-cad protein levels 
were assessed to further characterize these new models. 
 
4.2.2 Biochemical Characterization During Differentiation of the 2D Intestinal 
Epithelial Monolayer 
 
 To characterize the differentiation and/or proliferative state of the 2D-monolayers, which can be 
cultured in non-differentiating and differentiating conditions, several analyses to assess the expression of a 
series of proteins were made by WB. The variation of CFTR protein levels among the three models was 
also analyzed.  
 In order to assess the differentiation state and infer the epithelial polarization, levels of E-cadherin 
(E-cad), N-cadherin (N-cad) and Cytokeratin 18 (CK18) were assessed (Figure 4.2). E-cad and N-cad are 
cell adhesion molecules that are present in adherens junctions, characteristic of polarized epithelial cells. 
N-cad is mostly expressed in mesenchymal-type cells while E-cad is expressed in highly differentiated 
epithelial cells, which means that after differentiation there is an increase in expression of E-cad and a 
decrease in N-cad
102
. CK18 is a cytoskeleton protein of the intermediate filament family. It is mainly a 
structural protein and is largely expressed in polarized and highly differentiated epithelial cells
103
. To 
assess the proliferative state of these cells, Ki-67 protein was analyzed. This protein was first identified in 
Hodgkin lymphoma cell nuclei as an antigen that is highly expressed in proliferative cells and strongly 
downregulated in quiescent and resting cells in the G0-phase
104,105
. Since then, Ki-67 has become a widely 
used cell proliferation marker.  
 WB analysis (Figure 4.2) showed that there is a decrease in Ki-67 protein levels in the 
differentiated 2D-monolayers when compared with the 3D-organoids and the undifferentiated 2D-
monolayers (grown in expansion media, i.e., non-differentiating conditions). Therefore, we can conclude 
that the 3D-organoids and the undifferentiated 2D-monolayers are cells in highly proliferative states. 
When we switch the 2D-monolayers to the differentiation media for 6 days, the cells lose their 
proliferative status, as shown by the decrease in the levels of Ki-67. We can also see that E-cad and CK18 
are elevated in the 2D-differentiated cells and N-cad is diminished. This is in agreement with the fact that 
the stem-like cells present in the bottom of the crypts (that are able to form the 3D-organoids) undergo 
differentiation until they reach the more differentiated cell types of the villi, such as enterocytes or goblet 
cells. Thus, our results show that the 2D-undifferentiated monolayers seem to be composed of crypt-base 
stem cells and transit-amplifying progenitor cells, and the 2D-differentiated monolayers of mainly 




Figure 4.2 – WB analysis of WT 2D undifferentiated and differentiated monolayers and 3D-organoids. For the assessment 
of the differentiation state amongst the 3 models, the levels of E-cad, N-cad and CK-18 were analyzed. The proliferation state of 
the cells was assessed by the protein levels of Ki-67. Also, CFTR protein levels were analyzed amongst the 3 models. GAPDH 
and Na+ K+ ATPase were used as loading controls. 3D – 3D organoids; 2D U – 2D undifferentiated monolayers; 2D D – 2D 
differentiated monolayers. 
 
 To characterize CFTR protein expression in this novel model we also analyzed CFTR protein 
expression by WB. Typically, WT-CFTR originates 2 bands in WB that depend on the glycosylation state 
of the protein. A more prominent band with 170-180 kDa corresponding to the fully glycosylated, mature 
CFTR (band C) and a fainter band of 150 kDa which is the ER core-glycosylated form of the protein 
(band B)
106
. Both the 3D-organoids and 2D-undifferentiated monolayers present an extensive CFTR band 
C and a fainter band B, suggesting high levels of processing efficiency and mature CFTR protein in the 
membrane. In the differentiated 2D-intestinal monolayers we can see a significant decrease in CFTR 
protein levels. It was described that CFTR expression in the large intestine is mainly found in the base of 
the crypts
107–110
, where the cells are essentially enrolled in fluid secretion whereas the enterocytes in the 
intestinal villi are responsible for absorptive processes and CFTR expression decreases111. Here, the 3D-
organoids and 2D-undifferentiated monolayers (mainly composed of LGR5
+
 stem cells) are representative 
of the crypt cells of the colon that express high levels of CFTR. Therefore, the 2D-differentiated 
monolayers consist of the differentiated cells of the colon in which CFTR expression is much lower. Thus, 
based on this information, for functional studies of CFTR activity and CFTR-mediated fluid secretion the 
2D-undifferentiated monolayer seems to be the most adequate model, along with the already used 3D-




4.2.3 Analysis of WT CFTR Basal Activity Using Ussing Chamber Experiments in 2D 
Intestinal Cell Cultures 
 
After confirming CFTR expression in the 2D-monolayers, CFTR function was assessed by Ussing 
chamber measurements, where samples from several individuals with CF with different mutations and 
non-CF controls were analyzed. Before the assessment of drug response in these intestinal 2D-cell cultures 
(see section 4.3), here we aimed to assess the basal CFTR activity of the 2D-monolayers in the Ussing 
chamber. For this, we used undifferentiated and differentiated monolayers from a WT donor, so as to 
compare the respective levels of CFTR function. The results are depicted in Figure 4.3. 
 
   
Figure 4.3 – Results from Ussing chamber measurements for basal activity in 2D-intestinal monolayers from a WT donor. 
Representative original recordings of the effects of cAMP-dependent (IBMX/Fsk (IF), 100µM/2µM, apical) activation, CFTR 
potentiation (Genistein, 25 µM, apical) and CFTR-specific inhibition (CFTRinh-172 (Inh172), 30µM, apical) on transepithelial 
voltage (Vte) in 2D intestinal epithelial monolayers from a WT donor. Experiments were performed in the presence of Amiloride 
(20 µM, apical) for: (A) undifferentiated monolayers; (B) differentiated monolayers (after 6 days of culture in differentiation 
media). Summary of activated equivalent short-circuit currents (ΔIeq-sc) upon: (C) IF addition for the two models; (D) Inh172 
addition for the two models. Data represent the mean of measurements on 4 replicates per condition ± SD. The comparisons in (C) 
and (D) are not significant according to an unpaired T-test. 
 After adding Amil, we can immediately see that there is no change in voltage (Figure 4.3A,B), 
which is not surprising given the low amount of ENaC mRNA observed (Figure 4.3). Combined, these 
results indicate that ENaC expression is very low and thus we could not measure any function. When 
IBMX/Fsk (IF) is added in both conditions, in order to raise the levels of intracellular cAMP and elicit 
CFTR-mediated Cl
-
 secretion, we see a negative deflection, as expected when using a WT donor sample 
due to active CFTR (Figure 4.3A,B). However, looking at the amount of current produced by IF 
stimulation on both conditions, we do see a decrease in CFTR-dependent current in the differentiated 2D-
monolayers, although not significant (Figure 4.3C). This effect is also seen in the CFTRinh-172 response 
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(Figure 4.3D). This can be explained by the lower levels of CFTR protein expression observed upon 
differentiation as discussed in section 4.2.1, which is also in agreement with what is known about CFTR 
expression and function in the crypt-base stem cells vs. differentiated villi cells. Nevertheless, the currents 
measured are not as low as would be suggested by the low expression levels of CFTR protein in the 
differentiated 2D-monolayers. This could be due to differences in differentiation of the 2D-monolayers 
analyzed in the Ussing chamber vs. the ones analyzed in the WB or, more likely the fact that even low 
expression of WT CFTRs may be enough to produce a considerable CFTR-generated current. 
 As this chapter’s goal was to characterize the 2D-monolayers derived from 3D-organoids, we can 
reach several conclusions from these preliminary experiments: 
1) We can observe from the differentiation markers analysis that these 2D-monolayers differentiate 
quickly, as after only 6 days in differentiation media we observed a significant decrease in cell 
proliferation and an increase in proteins characteristic of polarized epithelial cells, namely E-cad 
and CK18; 
2) Upon intestinal epithelial differentiation, CFTR protein levels decrease, which is also expected 
due to the change in CFTR expression in the colon crypts/villi. 
3) From the functional analyses, we determined that the CFTR-mediated Cl- currents are diminished 
in the differentiated vs non-differentiated monolayers. 
Therefore, for the subsequent experiments, we used undifferentiated 2D-intestinal monolayers for further 
assessment of CFTR function and rescue in 2D-monolayers with different CFTR genotypes. 
 
4.3 Comparison of CFTR Function Assessment Between Rectal Biopsies 
and 2D Intestinal Monolayers 
 
 Our aim here was to compare the basal CFTR function assessment (with no drugs) in the rectal 
biopsies from individuals with CF with the basal function that can be assessed in the 2D-intestinal 
monolayers of the same individuals. The potential use of these 2D-monolayers for the same purpose of the 
fresh tissue would bring certain advantages. We would not be dependent on tissue quality of the biopsy 
and also would not be restrained by the short-time limitations of tissue viability, preventing the need to 
collect the biopsies as close as possible to the laboratory where the analysis will be performed. This is of 
particular interest for centres which do not have electrophysiological tests in place, as they could benefit 
from shipping the samples to others which have. Moreover, given these limitations, using the 2D-
monolayers would avoid the need to repeat the biopsies upon failure of the analysis, ruling out the 








 To first compare CFTR function in the 2D-monolayers of intestinal cells derived from a non-CF 
(wt/wt) donor with that in the rectal biopsies, CFTR function was measured in the Ussing chamber using 
the same protocol (Figure 4.4).  
 Ussing chamber recordings of transepithelial voltage of the wt/wt donor rectal biopsies (Figure 
4.4A) show a transient negative deflection upon basolateral cholinergic stimulation with CCH, evidencing 
a predominance of CFTR-mediated Cl
- 
currents. Sequentially, the second CCH stimulation (now in the 
presence of indomethacin, Indo) shows a transient positive voltage deflection due to global luminal K
+
 
secretion, since in this case, Cl
-
 secretion is inhibited due to the abolishment of intracellular cAMP 





. Subsequently, and still in the presence of Indo, IBMX/Fsk was added to elicit an increase 
in intracellular cAMP concentration, thus stimulating CFTR and generating a negative voltage due to 
CFTR activity. Finally, a third CCH stimulation was performed in the presence of the previous stimuli 
(Fsk/IBMX) and provoked a very large and transient negative peak, demonstrative of CFTR maximal 
activation. These results evidence the typical response of a wt-CFTR using this protocol
75
. 
 Transepithelial voltage of the wt 2D-intestinal monolayers was also recorded in the Ussing 
chamber in the exact same conditions (Figure 4.4B). The first CCH stimulation in the 2D-monolayers 
produced the same type of response as in the fresh tissue, despite with some delay. However, the effect of 
the second CCH stimulation in the 2D-monolayers was different from that in the fresh tissue. In the rectal 




 channels that are present in the apical and 
basolateral membranes of colonic epithelial cells
112
. As the response observed in the rectal biopsies is a 
positive voltage deflection, we can conclude that the luminal K
+
 secretion is larger than the basolateral 
absorption, so the net current elicited by K
+
 exit is positive. In the case of the 2D-monolayers, we 
observed a negative voltage deflection. This could eventually be due to larger K
+
 currents corresponding 
to exit at the basolateral side, causing the net current to be negative. Further experiments are necessary to 
confirm this hypothesis. Upon stimulation with IBMX/Fsk, a negative deflection was observed in the 
monolayers, as expected, confirming CFTR function, and this was larger than that observed in the rectal 
biopsies. Finally, CCH elicited in the 2D-intestinal monolayers a large and brief negative voltage peak as 
observed in the rectal biopsies. Overall, we can confirm that the effects seen in the 2D-intestinal 
monolayers are similar to those observed in the fresh tissue, despite the discrepancy observed in the CCH 




Figure 4.4 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from a WT donor. 
Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and cAMP-dependent (IBMX/Fsk, 
100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in a WT donor: (A) Rectal biopsies; (B) Undifferentiated 2D 
intestinal monolayers. Experiments were performed in the presence of Amiloride (Amil, 20 µM, apical) and/or Amiloride + 
Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (C) and (D) Summary of activated equivalent short-circuit 
currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo 
(ΔIeq-sc,IBMX/Fsk(Indo)) and CCH following IBMX/Fsk application (ΔIeq-sc,CCH(IBMX/Fsk(Indo))); data represent the mean 
of measurements of 3 replicates ± SD. 
 Following the Ussing chamber experiments with the undifferentiated 2D-monolayers, we applied 
the same protocol used in the biopsies to the differentiated 2D-intestinal monolayers to assess how the 
reduced protein levels of CFTR (as described early in section 4.2.2) affect the Ussing chamber readout 
(Figure 4.5).  
 If we compare the undifferentiated 2D-monolayer tracing (Figure 4.5B) with that of the 
differentiated 2D-monolayer tracing (Figure 4.5A), we can observe that for the first CCH stimulation the 
responses are quite similar, albeit smaller but faster in the differentiated 2D-monolayers. This may be due 
to the lower levels of CFTR and, consequently, the lack of the CFTR characteristic kinetics. However, 
when we observe the second stimulation of CCH (in the presence of Indo to ablate the intracellular levels 
of cAMP), the negative deflection produced in the 2D-differentiated monolayers is both larger and faster 
when compared with the that in the 2D-undifferentiated monolayers, which may be CFTR-related or 
influenced by the presence of different K
+
 channels or still due to differences in the expression levels of 
these (or other) channels. Accordingly, and because we still do not know if the same ion channels, namely 
K
+
 channels, are equally present in the 2D-differentiated and 2D-undifferentiated monolayers, as well as 
their distribution, we cannot yet attribute the difference observed in this CCH stimulation to reduced 
levels of CFTR only. Moreover, the first and second CCH responses in the differentiated 2D-monolayers 
(Figure 4.5B) produce very similar currents, further supporting the lack of role of cAMP stimulation in 
these responses. Then, when we stimulate both types of 2D-monolayers with IBMX/Fsk, still in the 
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presence of Indo, we can observe that the voltage change is much smaller in the 2D-differentiated 
monolayers, reinforcing that the reduced cAMP-stimulated CFTR-mediated Cl
-
 secretion in these is 
consistent with the decreased protein expression (see section 4.2.2). Next, when the 2D-monolayers were 
further stimulated with CCH under IBMX/Fsk, we can observe a negative peak in voltage that is bigger in 
the 2D-differentiated cells than in the 2D-undifferentiated cells. This can be due to the fact that the 
IBMX/Fsk stimulation in the 2D-undifferentiated monolayers already induces near-maximal activation of 
the CFTR protein. Moreover, as the IBMX/Fsk response is smaller in the differentiated monolayers, then 
the cells are not so depolarized and CCH further depolarizes the cells, in a transient response that is 
rapidly restored to the levels of Indo + IBMX/Fsk stimulation. However, the fact that in the 2D-
differentiated monolayer experiment, the final addition of CFTRinh-172 ablates the IF-specific current, 
suggests that this response is CFTR-specific, unless, as some authors report, the CFTRinh-172 is not 
entirely specific for the CFTR ion channel
113
. 
 Overall, these results can assist in the further characterization of undifferentiated and 
differentiated 2D-monolayers, although more experiments testing other conditions should be performed in 




Figure 4.5 - Results from Ussing chamber measurements in differentiated 2D-monolayers from a WT donor. 
Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and cAMP-dependent (IBMX/Fsk, 
100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in the WT donor: (A) differentiated intestinal epithelial 
monolayers. Experiments were performed in the presence of Amiloride (Amil, 20 µM, apical) and/or Amiloride + Indomethacin 
(Indo, 10 µM, basolateral), as indicated in the figure. (B) Summary of activated equivalent short-circuit currents (ΔIeq-sc) for 
Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-
sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-sc,CCH(IBMX/Fsk(Indo))) and Inh172 following 










 To confirm whether the results seen in the previous section were not restricted to wt/wt samples 
and how mutations in CFTR affect the Ussing chamber readouts of 2D-monolayers derived from 3D-
organoids, 2D-monolayers from an individual (CFL59) with a high residual function mutation 
(F508del/S955P genotype) were analyzed and the tracings were compared with those of rectal biopsies 
from the same individual (Figure 4.6). 
 Analysis of the Ussing chamber recordings of voltage measurements in rectal biopsies (Figure 
4.6A) shows a positive K
+ 
secretory response after basal cholinergic stimulation by CCH, already 
indicating a lack of Cl
-
 secretion through CFTR. After IBMX/Fsk addition to stimulate cAMP-dependent 
Cl
-
 secretion, there is a negative deflection in voltage meaning that there is residual CFTR activity that is 
further increased by the basal stimulation with CCH. This last CCH stimulation is presented in a 
monophasic manner, much like a wt-CFTR response (see figure 1.6A). However, the overall current is 
~7.5% of that in wt/wt CFTR biopsies. This means that this individual has a relatively high CFTR residual 
activity for an individual with CF.  
 In the analysis of the CFL59 2D-monolayers, unlike the rectal biopsies, in the first two basal CCH 
stimulations we observe two negative deflections instead of two positive responses (Figure 4.6B). The 
second CCH negative deflection (in the presence of Indo) is smaller than the first CCH, and this might be 
explained by the fact that, in the first stimulation, there could be the combination of currents from CFTR-
mediated Cl
-
 secretion and a larger basolateral K
+ 
currents corresponding to K
+ 
exit, while in the second 
CCH stimulation only the basolateral K
+ 
exit is producing those smaller currents. The stimulation with 
IBMX/Fsk shows a clear CFTR activation and the final CCH increased the current only slightly, perhaps 
due to “near-to-maximal” activation with just IBMX/Fsk. Still, when compared with the ones in the rectal 
biopsies, the overall currents calculated for the 2D-monolayers are smaller. These last currents were 
abolished by the use of CFTRinh-172, which indicates that they were generated due to CFTR-mediated Cl
-
 
secretion, suggesting residual CFTR activity. Overall, both tracings from the biopsies and the 2D-
monolayers indicate that there is residual CFTR activity, highlighted by the extent of the negative voltage 
deflection upon IBMX/Fsk and IBMX/Fsk+CCH stimulation and, in the case of the 2D-monolayers, the 
use of CFTRinh-172 to inhibit these responses further supports its CFTR specificity. Additionally, the FIS 




Figure 4.6 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from individual CFL59 
(F508del/S995P genotype). Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and 
cAMP-dependent (IBMX/Fsk, 100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in CFL59 (F508del/S995P 
genotype): (A) Rectal biopsies; (B) Undifferentiated 2D intestinal monolayers. Experiments were performed in the presence of 
Amiloride (Amil, 20 µM, apical) and/or Amiloride + Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (C) and 
(D) Summary of activated equivalent short-circuit currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + 
Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-
sc,CCH(IBMX/Fsk(Indo))) and Inh172 following CCH/IBMX/Fsk application (ΔIeq-sc, Inh172 (CCH(IBMX/Fsk(Indo)))), in the 
2D intestinal monolayers; data represent the mean of measurements of 4 rectal biopsies and 3 monolayers ± SD. [Ussing chamber 




 Another individual analyzed was CFL54 who had the F508del/R347P genotype. Ussing chamber 
recordings and quantification of the rectal biopsies and 2D-monolayers were analyzed (Figure 4.7). 
 The original Ussing chamber tracings for  rectal biopsies from individual CFL54 (Figure 4.7A) 
show two positive deflections upon the first two CCH stimulations that imply only net K
+
 secretion, a 
small negative voltage change in response to IBMX/Fsk administration and a biphasic type response 
(Figure 1.6B) upon the final CCH stimulation indicating some cAMP-stimulated Cl
-
 secretion. This 
tracing suggests that the individual has low residual function that should result in a mild CF phenotype. 
Indeed, this IBMX/Fsk response is also demonstrated with the 2D-monolayers (Figure 4.7 B), were there 
is a large negative voltage change in response to IBMX/Fsk stimulation, suggesting cAMP-generated 
CFTR-mediated Cl
-
 currents, that are further enhanced by CCH addition. In comparison to the previous 
35 
 
individual, results show that both rectal biopsies and 2D-monolayers from CFL59 evidence larger CFTR 
residual activity than those of CFL54. So, both models indicate that there is residual CFTR activity in the 
CFL54 individual, thus being expected to have a non-classic CF phenotype (Table 4.1). Moreover, the FIS 
assay in 3D-organoids of this individual also demonstrates swelling with just Fsk (Figure 4.14), 
reinforcing these results. 
 
Figure 4.7 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from individual CFL54 
(F508del/R347P genotype). Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and 
cAMP-dependent (IBMX/Fsk, 100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in CFL54 (F508del/R347P 
genotype): (A) Rectal biopsies; (B) Undifferentiated 2D intestinal monolayers. Experiments were performed in the presence of 
Amiloride (Amil, 20 µM, apical) and/or Amiloride + Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (C) and 
(D) Summary of activated equivalent short-circuit currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + 
Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-
sc,CCH(IBMX/Fsk(Indo))) and Inh172 following CCH/IBMX/Fsk application (ΔIeq-sc, Inh172 (CCH(IBMX/Fsk(Indo)))), in the 
2D intestinal monolayers; data represent the mean of measurements of 4 rectal biopsies and 3 monolayers ± SD. [Ussing chamber 




 CFL75 has the F508del/R334W genotype, being R334W a class IV mutation that allows for 




. So, in this individual’s rectal biopsies (Figure 
4.8A) there are two positive deflections upon CCH stimulation, which indicate that there is K
+
 exit but no 
Cl
-
 currents, consistent with a diagnosis of CF. However, after IBMX/Fsk stimulation there is a negative 
deflection that suggests cAMP-activated CFTR-mediated Cl- secretion. However, after adding the final 
CCH solution, we see a positive deflection in a monophasic manner, indicating that the low CFTR activity 
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in the tissue from this individual is not enough to compensate for the K
+
 exit from the cell. Therefore, 
individual CFL75 should have some low residual CFTR activity but not in a magnitude that would allow 
detection of a biphasic response upon CCH stimulation in the presence of IBMX/Fsk. 
  Similar results were found in the 2D-intestinal monolayer analysis (Figure 4.8B), where there was 
a clear negative deflection in response to IBMX/Fsk and further potentiated by CCH addition. These 
overall results reinforce the conclusion that individual CFL75 seems to have residual CFTR function, 
which was also observed in the FIS assay (Figure 4.18). 
 
Figure 4.8 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from individual CFL75 
(F508del/R334W genotype). Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and 
cAMP-dependent (IBMX/Fsk, 100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in CFL75 (F508del/R334W 
genotype): (A) Rectal biopsies; (B) Undifferentiated 2D intestinal monolayers. Experiments were performed in the presence of 
Amiloride (Amil, 20 µM, apical) and/or Amiloride + Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (C) and 
(D) Summary of activated equivalent short-circuit currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + 
Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-
sc,CCH(IBMX/Fsk(Indo))) and Inh172 following CCH/IBMX/Fsk application (ΔIeq-sc, Inh172 (CCH(IBMX/Fsk(Indo)))), in the 








4.4.3 Severe CFTR Mutations 
 
4.4.3.1  F508del/G542X 
 
 To determine whether CFTR activity in these 2D-monolayers was consistently dependent on the 
CFTR residual activity observed in the rectal biopsies, we analyzed samples from a severe CF genotype 
namely, rectal biopsies and 2D-intestinal cell monolayers from individual CFL61’s (F508del/G542X 
genotype) in the Ussing chamber.  
 The Ussing chamber recordings in the rectal biopsies (Figure 4.9A) show three positive 
deflections upon CCH stimulation and no response to IBMX/Fsk stimulation. This demonstrates that there 
is no CFTR-mediated Cl
-
 secretion and only a net positive current from luminal K
+
 secretion. This is a 
hallmark response of an individual with CF with a severe phenotype
75
 (see Figure 1.6C).  
 
Figure 4.9 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from individual CFL61 
(F508del/G542X genotype). Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and 
cAMP-dependent (IBMX/Fsk, 100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in CFL61 (F508del/G542X 
genotype): (A) Rectal biopsies; (B) Undifferentiated 2D intestinal monolayers. Experiments were performed in the presence of 
Amiloride (Amil, 20 µM, apical) and/or Amiloride + Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (C) and 
(D) Summary of activated equivalent short-circuit currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + 
Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-
sc,CCH(IBMX/Fsk(Indo))) and Inh172 following CCH/IBMX/Fsk application (ΔIeq-sc, Inh172 (CCH(IBMX/Fsk(Indo)))), in the 
2D intestinal monolayers; data represent the mean of measurements of 4 rectal biopsies and 3 monolayers ± SD. [Ussing chamber 
measurements in the rectal biopsies were performed by Raquel Centeio and used with permission] 
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 The recordings in the 2D-intestinal monolayer (Figure 4.9B) show three negative deflections upon 
CCH stimulation and a much smaller IBMX/Fsk-stimulated voltage change when compared to either 
wt/wt cells (Figure 4.4) or those with high residual function (Figure 4.6). These results suggest that there 
is no detectable Cl
-
 secretion involved and the negative voltage deflections are the result of net negative 
currents derived from basolateral K
+
 exit. Therefore, we suggest that this should be considered a typical 




 Another individual analyzed was CFL65 who had the F508del/F508del genotype, the most 
common CF genotype. This mutation results in a severe lack of CFTR function due to protein misfolding, 
which is evidenced by the three positive peaks resulting from CCH stimulation of the individual’s rectal 
biopsies (Figure 4.10A), a classic CF Ussing chamber tracing. Nonetheless, there is a slight negative 
voltage variation in response to IBMX/Fsk stimulation, suggesting some basal CFTR activity, as also 
shown in the 3D-organoid swelling (Figure 4.21). This was previously reported to occur for a small 
number of individuals with the F508del/F508del genotype
74
. 
 In the 2D-monolayers (Figure 4.10B), two negative peaks were observed in response to the first 
and second CCH stimulation and also a negative voltage shift when IBMX/Fsk is introduced to stimulate 
CFTR. This last response indicates that there is still some cAMP-mediated Cl
-
 secretion in cells from this 
individual which is in agreement with what was observed in this individual’s rectal biopsies and 3D-
organoids (Figure 4.20). It is of note that the IBMX/Fsk response reaches a negative peak and rapidly the 
voltage begins to increase, which can be due to CFTR membrane protein internalization and degradation, 
since the F508del-CFTR has low stability at the PM
116
. Further stimulation with CCH only caused a 
reduced negative deflection, suggesting that CFTR activity could not be further increased. Lastly, the 
addition of CFTR-Inh172 raised the voltage until the levels prior to the IBMX/Fsk stimulation, indicating 




Figure 4.10 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from individual CFL65 
(F508del/F508del genotype). Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and 
cAMP-dependent (IBMX/Fsk, 100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in CFL65 (F508del/F508del 
genotype): (A) Rectal biopsies; (B) Undifferentiated 2D intestinal monolayers. Experiments were performed in the presence of 
Amiloride (Amil, 20 µM, apical) and/or Amiloride + Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (C) and 
(D) Summary of activated equivalent short-circuit currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + 
Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-
sc,CCH(IBMX/Fsk(Indo))) and Inh172 following CCH/IBMX/Fsk application (ΔIeq-sc, Inh172 (CCH(IBMX/Fsk(Indo)))), in the 
2D intestinal monolayers; data represent the mean of measurements of 4 rectal biopsies and 3 monolayers ± SD. [Ussing chamber 
measurements in the rectal biopsies were performed by Raquel Centeio and used with permission] 
 
 Another individual with the F508del/F508del genotype - CFL80 - was analyzed (Figure 4.11). In 
the original representative tracing of the rectal biopsies (figure 4.11A) it is harder to distinguish the CCH-
stimulated responses, because the biopsies were of lower quality. This is one of the problems that could be 
avoided in the analysis of the 2D-monolayers. Anyhow, there are three positive deflections present upon 
CCH stimulation that are consistent with a classical CF phenotype. Nonetheless, there is a small response 
to IBMX/Fsk that may indicate some basal CFTR activity, like it was evidenced in the FIS assay (Figure 
4.23). 
 Next, 2D intestinal monolayers from the CFL80 individual were also analyzed in the Ussing 
chamber (Figure 4.11B). Again, there are two negative deflections in response to the first and second CCH 
stimulation and an IBMX/Fsk response that indicates that there is some cAMP-stimulated Cl
-
 secretion 
like in the rectal biopsies and 3D-organoids from this individual. Comparable with the CFL65 IBMX/Fsk 
response, cells from this individual also evidenced an increase in voltage in the second half of the 
IBMX/Fsk stimulation and further stimulation with CCH decreased the voltage, which suggests an 
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increase in CFTR activity. In the end, application of CFTR-Inh172 ablated both these last currents, 
indicating that they were CFTR specific. Overall, albeit the response in cells from individual CFL80 was 
smaller than those in cells from CFL65, both tracings are comparable for these two F508del/F508del 
genotypes.  
 
Figure 4.11 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from individual CFL80 
(F508del/F508del genotype). Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and 
cAMP-dependent (IBMX/Fsk, 100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in CFL80 (F508del/F508del 
genotype): (A) Rectal biopsies; (B) Undifferentiated 2D intestinal monolayers. Experiments were performed in the presence of 
Amiloride (Amil, 20 µM, apical) and/or Amiloride + Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (C) and 
(D) Summary of activated equivalent short-circuit currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + 
Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-
sc,CCH(IBMX/Fsk(Indo))) and Inh172 following CCH/IBMX/Fsk application (ΔIeq-sc, Inh172 (CCH(IBMX/Fsk(Indo)))), in the 
2D intestinal monolayers; data represent the mean of measurements of 3 rectal biopsies and 3 monolayers ± SD. 
 
 Afterwards, the intestinal 2D-monolayers of patient CFL80 were cultured in differentiating 





Figure 4.12 - Results from Ussing chamber measurements in differentiated 2D-monolayers from individual CFL80 
(F508del/F508del genotype). Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and 
cAMP-dependent (IBMX/Fsk, 100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in CFL80 (F508del/F508del): 
(A) differentiated intestinal epithelial monolayers. Experiments were performed in the presence of Amiloride (Amil, 20 µM, 
apical) and/or Amiloride + Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (B) Summary of activated 
equivalent short-circuit currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + Indo (ΔIeq-
sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-
sc,CCH(IBMX/Fsk(Indo))) and Inh172 following CCH/IBMX/Fsk (ΔIeq-sc, Inh172 (CCH(IBMX/Fsk(Indo))) application; data 
represent the mean of measurements of 3 replicates ± SD. 
 
 In the differentiated intestinal 2D-monolayers we can observe stronger CCH currents (Figure 4.12 





channels. There is a similar IBMX/Fsk response in both undifferentiated and 
differentiated 2D-monolayers that is abolished by the use of CFTRinh172, even though the differentiated 
2D-monolayers have much lower levels of CFTR protein expression. This current could be originated 
from the activity of other cAMP-activated ion channels, since there have been reports that the CFTR inh172 






 For individual CFL70, who had the F508del/A561E genotype, rectal biopsies and 2D-intestinal 
cell monolayers were analyzed in the Ussing chamber (Figure 4.13). A561E is a class II mutation that 
causes protein trafficking impairment. Indeed, observing the representative Ussing chamber recording 
from the rectal biopsies (Figure 4.13A), the three positive deflections after CCH addition, characteristic of 
a classical CF phenotype, are present, as well as the lack of negative deflection after IBMX/Fsk 
stimulation, indicating that there is no cAMP-activated Cl
- 
secretion, and therefore no CFTR activity. 
However, the same is not represented in the 2D-monolayer analysis (Figure 4.13B), where there is a small 
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negative deflection associated with IBMX/Fsk addition, suggesting some residual CFTR activity. There 
were also three distinctive negative peaks upon CCH stimulation, being the first CCH addition (without 
Indo) the more negative one, which may indicate Cl
-
 secretion summed with K
+ 
channels-derived currents. 
The FIS assay of this individual also revealed some swelling with just Fsk (Figure 4.24), meaning that 
there might be some CFTR function measured in the 2D-monolayers and in 3D-organoids, which is not 
detected in the rectal biopsies. This may be due to a lower sensitivity of the rectal biopsy readout 
compared to the 2D-monolayers or to bad tissue quality, also reinforced by the very small responses. 
However, one way to test if there is some CFTR protein in the PM that could be active is to perform a WB 
analysis of cell lysates from cells from individual CFL70 and look for the presence of CFTR band C. This 
will be addressed in the future.  
 
 
Figure 4.13 – Results from Ussing chamber measurements in rectal biopsies and 2D-monolayers from individual CFL70 
(F508del/A561E genotype). Representative original recording of the effects of cholinergic (CCH, 100 µM, basolateral) and 
cAMP-dependent (IBMX/Fsk, 100µM/2µM, basolateral) activation on transepithelial voltage (Vte) in CFL70 (F508del/A561E 
genotype): (A) Rectal biopsies; (B) Undifferentiated 2D intestinal monolayers. Experiments were performed in the presence of 
Amiloride (Amil, 20 µM, apical) and/or Amiloride + Indomethacin (Indo, 10 µM, basolateral), as indicated in the figure. (C) and 
(D) Summary of activated equivalent short-circuit currents (ΔIeq-sc) for Amil (ΔIeq-sc,Amil), basal CCH (ΔIeq-sc,CCH), CCH + 
Indo (ΔIeq-sc,CCH(Indo)), IBMX/Fsk + Indo (ΔIeq-sc,IBMX/Fsk(Indo)), CCH following IBMX/Fsk application (ΔIeq-
sc,CCH(IBMX/Fsk(Indo))) and Inh172 following CCH/IBMX/Fsk application (ΔIeq-sc, Inh172 (CCH(IBMX/Fsk(Indo)))), in the 
2D intestinal monolayers; data represent the mean of measurements of 3 rectal biopsies and 3 monolayers ± SD. 
 After the analysis and the comparison of the Ussing chamber readouts of the individuals’ rectal 
biopsies and 2D-intestinal monolayers we can conclude that: 
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i) For the residual function and severe genotypes, the magnitude of the biopsy responses is 
higher than that in the 2D-monolayers; 
ii) For both residual function and severe genotypes, the first two CCH stimulations are negative 
in the 2D-monolayers and positive in the rectal biopsies; and 
iii) The last CCH stimulation is always negative in both models. 
 The reason for this last observation is yet to be clarified but it can be due to a change in overall 
ion channel expression and PM distribution (especially the K
+
 channels). Indeed, fresh biopsies consist in 





 stem cells from the bottom of the colonic crypts. However, in the 2D-monolayers, the 
tracings are distinguishable between the residual CFTR activity genotypes and the severe CF genotypes, 
indicating that these 2D-monolayer assays can distinguish between these two major phenotypes. 
 
4.4 Comparison of CFTR Functional Rescue Between 2D and 3D Models 
 
 After the comparison of CFTR basal function assessment between rectal biopsies and 2D-
intestinal epithelial monolayers, we aimed to compare the CFTR functional rescue with CFTR corrector 
and potentiator drugs in this novel 2D model (using Ussing chamber experiments) with the already 
established and validated 3D intestinal organoid model (using FIS assay).  
 




 One of the individuals with CF analyzed in this project is CFL54 who has the F508del/R347P 
genotype (Table 4.2). As mentioned before, F508del is a class II trafficking mutation that results in the 
lack of mature protein in the membrane. R347P is a mutation localized in TMD6 and was firstly described 
as a class IV conductance mutation that allows for protein maturation but results in poor Cl
-
 conductance 
in the membrane, having been associated with milder CF phenotypes, sometimes with some residual 
function. This was seen in Fisher Rat Thyroid cells expressing mutant R347P-CFTR analyzed by the 
whole-cell patch-clamp technique
114
. Nevertheless, recently the hypothesis of R347P not being a ‘pure’ 
class IV mutation has been proposed. In assays using patient-derived materials it was reported that R347P 
causes a folding defect similar to other class II mutations and that this mutant only matures to ~15% of 
WT levels. So, it is possible that the R347P not only has a conductance deficiency like class IV mutations 
but also a trafficking deficit similar to class II mutations
115
. 
 CFTR function was assessed in the 3D-intestinal organoids derived from this individual’s rectal 
biopsies (Figure 4.14). In the FIS assay, Fsk raises the intracellular cAMP concentration, which in turn 
activates CFTR and allows for CFTR-dependent fluid secretion to the lumen of the organoid. So, if CFTR 
is functional the organoid swells. In this assay, CF114 organoids (with S1251N/F508del genotype) were 
44 
 
used as a positive control. S1251N is a class III gating mutation for which the potentiator VX-770 was 
already shown to be effective and approved for clinical use
85
. Thus, S1251N/F508del organoids are 
suitable reference controls to compare the responses of organoids with unknown responses
45
. Therefore, as 
the control organoids only swell at 0.8 µM of Fsk, we analyzed the drug response of CFL54’s organoids at 
this concentration (Figure 4.14). 
 Statistical analysis of the data by one-way ANOVA using Dunnet’s multiple comparison test 
showed that there is no significant differences between Fsk alone and Fsk + VX-770 or Fsk + VX-661, but 
there is a statistically difference with VX-661/770 treatment. This means that VX-770 alone is not 
sufficient to correct the diminished Cl
- 
conductance caused by these two mutations (F508del/R347P) in 
this individual but to observe rescue it required the combined action of the corrector VX-661 and 
potentiator VX-770. This may be due to the fact that, R347P may not be a classic class IV mutation since 
it also impairs protein trafficking due to folding defects, and it was observed that it requires a corrector to 
either increase traffic to the cell membrane or function at this location
115
. However, it may also be due to 
the presence of F508del, which is classical Class II mutation. 
 
Figure 4.14 – Results from the FIS assay on 3D-intestinal organoids from individual CFL54 (F508del/R347P genotype). 
(A) Representative original confocal microscopy images of 3D intestinal organoids from individual CFL54 (F508del/R347P 
genotype) at times 0 and 60 min of incubation with the following treatments: Forskolin (Fsk) alone at the concentration of 0.8 
µM, VX-770 (3 µM) + Fsk, VX-661 (3 µM) + Fsk and VX-661/770 + Fsk. (B) Quantification of FIS in organoids for all 
treatments at Fsk concentrations 0.02, 0.128, 0.8 and 5 µM, expressed as the area under the curve (AUC) of organoid surface area 
increase (baseline = 100%, t = 60 min). (C) Quantification of CFL54 organoid swelling for all treatments at [Fsk] = 0.8 µM. 
Control organoids CF114 (S1251N/F508del genotype) were used as reference. (B) and (C) data represent the mean of 
measurements on 3-4 replicates for condition ± SD. Asterisks (*) represent the degree of significance calculated by an unpaired 
one-way ANOVA using Dunnet’s test, ** indicate a p-value<0.01. [Experiments were performed in collaboration with Iris Silva 
and included with permission]. 
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 Next, 2D-monolayers were generated from the 3D-organoids from this individual and tested in the 
Ussing chamber. The results are in Figure 4.15. The monolayers were incubated with Amil to inhibit any 
ENaC current and then stimulated with IF to elicit cAMP-mediated CFTR-derived Cl
-
 currents, which 
were further potentiated by the use of VX-770. Lastly, the Inh172 was added to block CFTR currents. 
Results show a negative voltage response for IF in the 2D-monolayers treated with DMSO, suggesting 
some residual activity at this Fsk concentration (0.8 µM) that was further potentiated by the addition of 
VX-770 (although not significant). The corrector VX-661 response alone generated an increase in the IF 
current greater than the VX-770 alone, reinforcing the conclusion that the R347P mutation is also a class 
II mutation, as discussed previously. At last, the combination therapy, VX-661/VX-770, creates a 
significant increase in the CFTR-derived Cl
-
 currents, which shows that, for this individual with CF, the 
CFTR rescue measured in the FIS assay using 3D intestinal organoids and in the Ussing chamber using 
2D monolayers are in agreement for the therapy that this individual with CF would benefit the most. 
 
 
Figure 4.15 – Results from Ussing chamber measurements in 2D-intestinal monolayers from individual CFL54 
(F508del/R347P genotype). Representative original recordings of the effects of cAMP-dependent (IBMX/Fsk (IF), 
100µM/0.8µM, apical) activation, CFTR potentiation (VX-770, 3 µM, apical) and CFTR-specific inhibition (CFTRinh-172 
(Inh172), 30µM, apical) on transepithelial voltage (Vte) in 2D intestinal epithelial monolayers from individual CFL54 
(F508del/R347P genotype). Experiments were performed in the presence of Amiloride (20 µM, apical) for: (A) 0.05% DMSO; 
(B) 3µM VX-661. (C) Summary of activated equivalent short-circuit currents in the presence of IBMX/Fsk (IF, 100 µM/0.8µM). 
Data represent the mean of measurements on 3 replicates per condition ± SD. Asterisks (*) represent the degree of significance 









 Individual CFL59 studied in this project had a F508del/S955P genotype. The S955P is a new and 
uncharacterized CFTR variant. There are no reports of individuals with this mutation in the literature or in 
common CF databases. It is located in the intracytoplasmic loop 4, connecting the RD to TMD7.  
 CFTR function was assessed in the individual’s 3D organoids (Figure 4.16) and with only 0.128 
µM of Fsk organoid swelling was already observed, suggesting a residual CFTR function (Figure 4.16 B-
C, black). At the same concentration, organoid swelling with the combination treatments VX-809/770 and 
VX-661/770 was significantly different from control and above the threshold for medium clinical benefit 
(Figure 4.16 B-C, blue and green). Due to the presence of an F508del-allele and the lack of information 
about S955P, it is hard to predict the effect of these CFTR modulators in S955P. Further cellular and 
functional effect and drug response characterization should be done in a relevant cell line, such as Cystic 




Figure 4.16 – Results from the FIS assay on 3D-intestinal organoids from individual CFL59 (F508del/S995P genotype). (A) 
Representative original wide-field microscopy images of 3D intestinal organoids from individual CFL59 (F508del/S995P 
genotype) at times 0 and 60 min of incubation with the following treatments: Forskolin (Fsk) alone at the concentration of 0.128 
µM, VX-770 (3 µM) + Fsk, VX-809 (3µM) + Fsk, VX-809/770 + Fsk, VX-661 (5 µM) + Fsk and VX-661/770 + Fsk. (B) 
Quantification of FIS in organoids for all treatments at Fsk concentrations of 0.02, 0.128, 0.8 and 5 µM, expressed as the area 
under the curve (AUC) of organoid surface area increase (baseline = 100%, t = 60 min). (C) Quantification of organoid swelling 
for all treatments at [Fsk] = 0.128 µM. The dashed blue and green line represent the established thresholds for medium and high 
clinical benefit potential for treatments, respectively. (B) and (C) data represent the mean of measurements on 3-4 replicates for 
condition ± SD. Asterisks (*) indicate degree of significant difference calculated by unpaired one-way ANOVA using Fisher’s 




 As for the previous individual, CFL59’s 2D-intestinal monolayers were generated from its 3D-
organoids and functional rescue of CFTR with approved modulators was assessed in the Ussing chamber 
(Figure 4.17). An IBMX/Fsk response (Figure 4.17 A,C) generating a large negative current could be 
observed, suggesting high residual CFTR activity. In fact, an unpaired one-way ANOVA using Dunnet’s 
multiple comparisons test showed that none of the three treatments (VX-770, VX-661 and VX-661/770) 
evidenced a statistically significant difference in relation to the control DMSO. This may be because of 
the high concentration of Fsk used in this experiment (2 µM), which by itself stimulated CFTR to an 
extent that a possible further effect by modulators could not occur. This experiment should be repeated in 
the future with lower concentration of Fsk to better evaluate the modulators effects.  
 
Figure 4.17 – Results from Ussing chamber measurements in 2D-intestinal monolayers from individual CFL59 
(F508del/S995P genotype). Representative original recordings of the effects of cAMP-dependent (IBMX/Fsk (IF), 
100µM/0.8µM, apical) activation, CFTR potentiation (VX-770, 3 µM, apical) and CFTR-specific inhibition (CFTRinh-172 
(Inh172), 30µM, apical) on transepithelial voltage (Vte) in 2D intestinal epithelial monolayers from individual CFL59 
(F508del/S995P genotype). Experiments were performed in the presence of Amiloride (20 µM, apical) for: (A) 0.05% DMSO; 
(B) 3µM VX-661. (C) Summary of activated equivalent short-circuit currents in the presence of IBMX/Fsk (IF, 100 µM/0.8µM). 




 Individual CFL75 who has an F508del/R334W genotype was also analyzed. R334W is a CF-
causing mutation located in the TMD6 and classified as class IV due to a high level of protein processing 
(98% of WT)
45
 but some groups showed that CFTR bearing this mutation has a very low conductance and 
a severely reduced open probability
114
.   
 3D-intestinal organoids from individual CFL75 were generated and CFTR function was assessed 
by the FIS assay (Figure 4.18). CF114 (S1251N/F508del genotype) was used as control since the S1251N 
is a class III gating mutation that is functionally rescued by VX-770 and R334W mutation, although is a 
class IV mutation, results in a CFTR protein with low open probability, and should also benefit from VX-
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770 alone. Since CF114’s organoids swelled at 0.8 µM of Fsk, that concentration was used to evaluate 
CFL75’s organoids swelling. The results show that, at this concentration of Fsk, there is already organoid 
swelling only with Fsk (Figure 4.18 A-C, black). Also, a positive effect on CFTR activity under 
potentiator VX-770, as well as with the VX-661/VX-770 combination was observed (Figure. 4.17B and 
C). These results were expected since R334W-CFTR traffics to the membrane in a manner that resembles 
WT-CFTR but, being a class IV mutation, has lower conductance
114
. Unfortunately, none of the therapies 
used significantly rescues CFTR function, so the results show that the probability of this individual with 
CF to benefit from any of the approved modulators tested in this experiment is low. Notwithstanding, the 
lack of additional swelling by modulators could be due to the fact that there is already considerable ‘basal’ 
pre-swelling as a consequence of the residual function associated with the R334W mutation. 
 
Figure 4.18 – Results from the FIS assay on 3D-intestinal organoids from individual CFL75 (F508del/R334W genotype). 
(A) Representative original confocal microscopy images of 3D intestinal organoids from individual CFL75 (F508del/R334W 
genotype) at times 0 and 60 min of incubation with the following treatments: Forskolin (Fsk) alone at the concentration of 0.8 
µM, VX-770 (3 µM) + Fsk, VX-661 (3 µM) + Fsk and VX-661/770 + Fsk. (B) Quantification of FIS in organoids for all 
treatments at Fsk concentrations 0.02, 0.128, 0.8 and 5 µM, expressed as the area under the curve (AUC) of organoid surface area 
increase (baseline = 100%, t = 60 min). (C) Quantification of CFL75 organoid swelling for all treatments at [Fsk] = 0.8 µM. 
Control organoids CF114 (S1251N/F508del genotype) were used as reference. (B) and (C) data represent the mean of 
measurements on 3-4 replicates for condition ± SD. [Experiments were performed in collaboration with Iris Silva and included 
with permission]. 
 
 Sequentially to the FIS assay, 2D-intestinal cell monolayers derived from this individual’s 
organoids were generated and analyzed in the Ussing chamber at the same concentration of Fsk (0.8 µM) 
(Figure 4.19). We can observe a large IBMX/Fsk response in the control monolayers (Figure 4.19 A, C), 
indicating residual CFTR function for this patient, as it was determined in the FIS assay (Figure 4.18). 
Nevertheless, contrary to what was observed in the FIS assay of the 3D-organoids, there is no potentiator 
VX-770 response in the 2D-intestinal monolayers, but there is a significant difference in the IBMX/Fsk 
current in the monolayers treated with VX-661 with the control monolayers. This can be due to the fact 
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that, in the Ussing chamber analysis for the control and treated 2D-monolayers, the IBMX/Fsk stimulation 
elicits a maximal CFTR activation, so there is no detectable further effect by the stimulation with 
potentiator VX-770 on CFTR activity. Moreover, corrector VX-661 might assist in the correction of the 
molecular defect caused by F580del (the second mutation in this individual) and perhaps also with some 
effect on R334W-CFTR. Nonetheless, more 2D-intestinal monolayers should be tested in the Ussing 




Figure 4.19 – Results from Ussing chamber measurements in 2D-intestinal monolayers from individual CFL75 
(F508del/R334W genotype). Representative original recordings of the effects of cAMP-dependent (IBMX/Fsk (IF), 
100µM/0.8µM, apical) activation, CFTR potentiation (VX-770, 3 µM, apical) and CFTR-specific inhibition (CFTRinh-172 
(Inh172), 30µM, apical) on transepithelial voltage (Vte) in 2D intestinal epithelial monolayers from individual CFL75 
(F508del/R334W genotype). Experiments were performed in the presence of Amiloride (20 µM, apical) for: (A) 0.05% DMSO; 
(B) 3µM VX-661. (C) Summary of activated equivalent short-circuit currents in the presence of IBMX/Fsk (IF, 100 µM/0.8µM). 
Data represent the mean of measurements on 3 replicates per condition ± SD. Asterisks (*) represent the degree of significance 











 Individual CFL61 analyzed in this project has the F508del/G542X genotype. G542X is a nonsense 
mutation localized in NBD1, which generates a premature stop codon (PTC) and has been demonstrated to 
severely reduce the levels of CFTR mRNA in nasal epithelial cells
117
. 2D-monolayers were generated for 
this individual and response to approved modulators was assessed (Figure 4.20). 
 
 
Figure 4.20 – Results from Ussing chamber measurements in 2D-intestinal monolayers from individual CFL61 
(F508del/G542X genotype). Representative original recordings of the effects of cAMP-dependent (IBMX/Fsk (IF), 
100µM/0.8µM, apical) activation, CFTR potentiation (VX-770, 3 µM, apical) and CFTR-specific inhibition (CFTRinh-172 
(Inh172), 30µM, apical) on transepithelial voltage (Vte) in 2D intestinal epithelial monolayers from individual CFL61 
(F508del/G542X genotype). Experiments were performed in the presence of Amiloride (20 µM, apical) for: (A) 0.05% DMSO; 
(B) 3µM VX-661. (C) Summary of activated equivalent short-circuit currents in the presence of IBMX/Fsk (IF, 100 µM/0.8µM). 
Data represent the mean of measurements on 3 replicates per condition ± SD. 
 
 In the control DMSO 2D-monolayers the results show no IBMX/Fsk response, implying that 
neither the truncated protein produced from the G542X allele nor the unfolded protein from the F508del 
allele have any residual function and this individual patient is expected to have a classical CF phenotype, 
which is in fact the case (Table 4.1). None of the approved CFTR modulators tested produced any 
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significant CFTR rescue when compared to the DMSO, so we hypothesize that the individuals with CF 
will not benefit from any of these therapies. Recently, it has been observed in HBE cells homozygous for 
the G542X mutation that the treatment with a combination of a read-through compound (G418) and the 
modulators VX-809/770 rescues some CFTR function
118
. Moreover, an Eloxx compound, ELX-02, is 
currently under Phase I trial (healthy subjects) and aims to correct genetic diseases causes by PTC 
mutations acting as a read-though compound
119
. Unfortunately, there are no approved read-through 
compounds that could eventually be tested in this individual’s organoids but it could be interesting for a 
future experiment to treat the 2D-intestinal monolayers with any read-through compound available and see 




 Individual CFL65 has the F508del/F508del CFTR genotype, which is the most common one. 
CFTR function was assessed in the 3D-intestinal organoids of the individual CFL65 by the FIS assay 
(Figure 4.21). 
 Even at low concentrations of Fsk there is already some swelling only with Fsk (Figure 4.21 B, 
black line), suggesting that there is some basal CFTR activity in this individual. At 0.8 µM of Fsk, both 
combination therapies (VX-809/770 and VX-661/770) rescue CFTR function to a significant extent 
(Figure 4.21B and C). This is in agreement to what was expected since these therapies have been approved 
for individuals with the F508del/F508del genotype
46,47
. So, from these results, we conclude that this 






Figure 4.21 – Results from the FIS assay on 3D-intestinal organoids from individual CFL65 (F508del/F508del genotype). 
(A) Representative original wide-field microscopy images of 3D intestinal organoids from individual CFL65 (F508del/F508del 
genotype) at times 0 and 60 min of incubation with the following treatments: Forskolin (Fsk) alone at the concentration of 0.128 
µM, VX-770 (3 µM) + Fsk, VX-809 (3µM) + Fsk, VX-809/770 + Fsk, VX-661 (5 µM) + Fsk and VX-661/770 + Fsk. (B) 
Quantification of FIS in organoids for all treatments at Fsk concentrations of 0.02, 0.128, 0.8 and 5 µM, expressed as the area 
under the curve (AUC) of organoid surface area increase (baseline = 100%, t = 60 min). (C) Quantification of organoid swelling 
for all treatments at [Fsk] = 0.8 µM. The dashed blue and green line represent the established thresholds for medium and high 
clinical benefit potential for treatments, respectively.. (B) and (C) data represent the mean of measurements on 3-4 replicates for 
condition ± SD. Asterisks (*) indicate degree of significant difference calculated by unpaired one-way ANOVA using Fisher’s 
LSD test, *** indicate a p-value<0.001 and **** indicate a p-value<0.0001. [Experiments were performed by Raquel Centeio and 
used with permission]. 
 
 Next, the 2D-monolayers derived from 3D-intestinal organoids from individual CFL65 were 
analyzed on the Ussing chamber for the effect of CFTR modulators (Figure 4.22). We can observe that the 
DMSO control has a small response to IF stimulation, suggesting some CFTR activity is detected as 
observed in the FIS assay (Figure 4.22), but with no further potentiation from VX-770. However, adding 
the corrector VX-661 leads to a clear increase in the IF-stimulated response that can be further potentiated 
by the use of the potentiator VX-770, demonstrating that there is rescue of this F508del-CFTR by the 
combination of these two modulators. This last current, the one generated by the combination VX-
661/770, is significantly different from the IF current under the DMSO control, thus this individual should 




Figure 4.22 - Results from Ussing chamber measurements in 2D-intestinal monolayers from individual CFL65 
(F508del/F508del genotype). Representative original recordings of the effects of cAMP-dependent (IBMX/Fsk (IF), 
100µM/0.8µM, apical) activation, CFTR potentiation (VX-770, 3 µM, apical) and CFTR-specific inhibition (CFTRinh-172 
(Inh172), 30µM, apical) on transepithelial voltage (Vte) in 2D intestinal epithelial monolayers from individual CFL65 
(F508del/F508del genotype). Experiments were performed in the presence of Amiloride (20 µM, apical) for: (A) 0.05% DMSO; 
(B) 3µM VX-661. (C) Summary of activated equivalent short-circuit currents in the presence of IBMX/Fsk (IF, 100 µM/0.8µM). 
Data represent the mean of measurements on 3 replicates per condition ± SD. Asterisks (*) represent the degree of significance 
calculated by an unpaired one-way ANOVA using Dunnet’s test, * indicate a p-value<0.05. 
 
 Similarly to CFL65, individual CFL80 has the F508del/F508del genotype and FIS assay was 
performed to evaluate CFTR functional rescue with the approved modulators (Figure 4.23).  
 Identical to CFL65, 3D-organoids from CFL80 evidence some swelling with just Fsk at 0.8 µM, 
suggesting that, again, there is already some F508del-CFTR in the PM. At the same concentration of Fsk, 
there is a significant difference between the swelling of the combination VX-661/770 and the Fsk control. 
Nevertheless, this is a small swelling response when compared to that of the CF114 control. So, we 
predict that this individual could have a modest clinical benefit with the administration of the combination 




Figure 4.23 – Results from the FIS assay on 3D intestinal organoids from individual CFL80 (F508del/F508del genotype). 
(A) Representative original confocal microscopy images of 3D intestinal organoids from individual CFL80 (F508del/F508del 
genotype) at times 0 and 60 min of incubation with the following treatments: Forskolin (Fsk) alone at the concentration of 0.8 
µM, VX-770 (3 µM) + Fsk, VX-661 (3 µM) + Fsk and VX-661/770 + Fsk. (B) Quantification of FIS in organoids for all 
treatments at Fsk concentrations 0.02, 0.128, 0.8 and 5 µM, expressed as the area under the curve (AUC) of organoid surface area 
increase (baseline = 100%, t = 60 min). (C) Quantification of CFL80 organoid swelling for all treatments at [Fsk] = 0.8 µM. 
Control organoids CF114 (S1251N/F508del genotype) were used as reference. (B) and (C) data represent the mean of 
measurements on 3-4 replicates for condition ± SD. Asterisks (*) represent the degree of significance calculated by an unpaired 
one-way ANOVA using Dunnet’s test, * indicate a p-value<0.05. 
 
 The individual’s intestinal 2D-epithelial cell monolayers were also analyzed for drug response in 
the Ussing chamber (Figure 4.24). We can observe that under DMSO (Figure 4.24 A, C), there is cAMP-
generated Cl- secretion upon IBMX/Fsk stimulation that can be further potentiated with the use of VX-
770). Nevertheless, in the monolayers treated with the corrector VX-661, there is no potentiator response 
following the IBMX/Fsk stimulation, unlike what was observed in the FIS assay. This can be explained by 
the maximal activation of CFTR in the treated monolayers with just IBMX/Fsk, which was at high 
concentration. Moreover, during the IBMX/Fsk stimulation there is a steady increase in voltage. This may 
be explained by CFTR internalization and degradation since F508del-CFTR is not stable at the PM
116
. For 
the modulator response, there is no significant difference between the treated monolayers and the control 
monolayers; unlike it was seen in the FIS assay where the swelling with the combination VX-661/770 was 
significantly different from the Fsk alone. So, from the 2D-intestinal monolayer analysis, we could not 





Figure 4.24 - Results from Ussing chamber measurements in 2D-intestinal monolayers from individual CFL80 
(F508del/F508del genotype). Representative original recordings of the effects of cAMP-dependent (IBMX/Fsk (IF), 
100µM/0.8µM, apical) activation, CFTR potentiation (VX-770, 3 µM, apical) and CFTR-specific inhibition (CFTRinh-172 
(Inh172), 30µM, apical) on transepithelial voltage (Vte) in 2D intestinal epithelial monolayers from individual CFL80 
(F508del/F508del genotype). Experiments were performed in the presence of Amiloride (20 µM, apical) for: (A) 0.05% DMSO; 
(B) 3µM VX-661. (C) Summary of activated equivalent short-circuit currents in the presence of IBMX/Fsk (IF, 100 µM/0.8µM). 




 Individual CFL70 has the F508del/A561E genotype. A561E is a missense mutation which, like 
F508del, is located in the NBD1 of the CFTR protein, and previously shown to impair folding and 
processing, causing a trafficking defect to the PM, much like the F508del mutation. Therefore, like 
F508del, A561E is considered a class II mutation
120
.  
 CFTR activity was measured in the 3D-organoids derived from this individual using the FIS assay 
(Figure 4.25). Similarly to CFL65, organoids from the CFL70 individual evidenced some organoid 
swelling at low Fsk concentrations (Figure 4.25 B, black line), indicative of some CFTR activity. 
Potentiator VX-770 or corrector VX-661 alone did not rescue CFRT function at [Fsk] = 0.8µM but the 
VX-661/VX-770 combination elicited a significant increase in the organoids swelling (Figure 4.25, 
orange). Therefore, our results show that this individual might benefit from the combination treatment. 
However, when compared to the CF114 control organoids, we predict that the clinical benefit would be 
modest. Authors have reported previously that the combined use of CFTR correctors and potentiators 
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partially rescue A561E-CFTR function
121
 and, as A561E presents a folding/traffic defect similar to that of 
F508del-CFTR (class II), the use of correctors might be expected to increase folding efficiency and 
membrane trafficking. Indeed, Ussing chamber recordings done in primary HBECs with a A561E/A561E 
genotype treated with VX-809 showed a rescue of CFTR activity similar to the rescue observed in HBECs 




Figure 4.25 - Results from the FIS assay on 3D-intestinal organoids from individual CFL70 (F508del/A561E genotype). (A) 
Representative original confocal microscopy images of 3D intestinal organoids from individual CFL70 (F508del/A561E 
genotype) at times 0 and 60 min of incubation with the following treatments: Forskolin (Fsk) alone at the concentration of 0.8 
µM, VX-770 (3 µM) + Fsk, VX-661 (3 µM) + Fsk and VX-661/770 + Fsk. (B) Quantification of FIS in organoids for all 
treatments at Fsk concentrations 0.02, 0.128, 0.8 and 5 µM, expressed as the area under the curve (AUC) of organoid surface area 
increase (baseline = 100%, t = 60 min). (C) Quantification of CFL70 organoid swelling for all treatments at [Fsk] = 0.8 µM. 
Control organoids CF114 (S1251N/F508del genotype) were used as reference. (B) and (C) data represent the mean of 
measurements on 3-4 replicates for condition ± SD. Asterisks (*) represent the degree of significance calculated by an unpaired 
one-way ANOVA using Dunnet’s test, ** indicate a p-value<0.01. 
 
 As for the analysis of 2D-monolayers in the Ussing chamber (Figure 4.26), the results show that 
in the presence of IBMX/Fsk there is only some very low CFTR-mediated Cl
-
 current in the DMSO 
control (Figure 4.26A, C), which is in agreement with the FIS assay in the 3D-organoids. Also in 
agreement with the 3D-organoids data is the fact that in the 2D-monolayers only the combination 




Figure 4.26 - Results from Ussing chamber measurements in 2D-intestinal monolayers from individual CFL70 
(F508del/A561E genotype). Representative original recordings of the effects of cAMP-dependent (IBMX/Fsk (IF), 
100µM/0.8µM, apical) activation, CFTR potentiation (VX-770, 3 µM, apical) and CFTR-specific inhibition (CFTRinh-172 
(Inh172), 30µM, apical) on transepithelial voltage (Vte) in 2D intestinal epithelial monolayers from individual CFL70 
(F508del/A561E genotype). Experiments were performed in the presence of Amiloride (20 µM, apical) for: (A) 0.05% DMSO; 
(B) 3µM VX-661. (C) Summary of activated equivalent short-circuit currents in the presence of IBMX/Fsk (IF, 100 µM/0.8µM). 
Data represent the mean of measurements on 3 replicates per condition ± SD. Asterisks (*) represent the degree of significance 
calculated by an unpaired one-way ANOVA using Dunnet’s test, ** indicate a p-value<0.05. 
 
 The data obtained for all individuals with CF from both analyses from the 3D-organoids and 2D- 
monolayers with the approved CFTR modulators are summarized in Table 4.2.  
Table 4.2 – Summary of 3D intestinal organoids and 2D intestinal monolayer analyses for all individuals studied. CFTR 
genotypes, individual codes, CFTR rescued observed in 3D organoids and 2D monolayers for all individuals studied at [Fsk] = 0.8 
µM. Asterisks (*) indicate the of statistical significant differences when compared to control, * indicate a p-value<0.05, ** 
indicate a p-value<0.01 and *** indicate a p-value<0.001. ns = not significant. NA = not available. 




















F508del/R347P CFL54 ns ns ** ns ns * 
F508del/S955P CFL59 ns ns * ns ns ns 




F508del/F508del CFL65 ns ns *** ns ns * 
F508del/A561E CFL70 ns ns ** ns ns ** 
F508del/G542X CFL61 NA NA NA ns ns ns 




 For all the individuals analyzed, the response observed in the 3D-organoids was compared with 
that in the 2D-monolayers. For 3 out of 7 individuals analyzed (CFL54, CFL65, CFL70), there was 
agreement between the FIS assay in the 3D-organoids and the Ussing chamber assay for the 2D-
monolayers because both analyses demonstrated significant difference between the combination VX-
661/770 and the DMSO control, meaning that there is rescue of CFTR function. For individual CFL75, we 
concluded that there is no rescue of CFTR function with the approved modulators in the FIS assay but the 
in 2D-monolayers there was significant rescue with just VX-661. For individual CFL80, there was a 
significant rescue of CFTR function with the combination VX-661/770 but no rescue was observed with 
the modulators in the 2D-monolayers. For individual CFL61 it is not possible to make the comparison 
since we did not obtain FIS data for this individual and for individual CFL59 the 2D-monolayer assay 
should be repeated with a lower concentration of Fsk. 
 In conclusion, we obtained mixed results regarding the correlations between drug response in 3D-
organoids and 2D-monolayers. Thus, more analyses from individuals with different mutations should be 
analyzed to test the validity of the 2D-monolayer assay to predict drug response and some of the ones 
already done here should be repeated under different conditions (e.g., lower Fsk concentrations, better 
washout of VX-770 from plastic tubes). 
 Lastly, to assess if the CFTR function parameters measured in these 2D-monolayers can be used 
to assess CFTR function, in the next subsection correlation studies were made between the 2D-monolayer 
data and the data from the rectal biopsies, 3D-organoids and clinical biomarkers. 
 
4.5 Correlations of CFTR Function Parameters and Clinical Data among 
Fresh tissue, 3D and 2D models 
 
 To establish the validity of the 2D model to assess CFTR function, correlations among fresh 






Table 4.3 – Summary of all data used for the correlation studies. Patient codes; CFTR genotype; activated short circuit currents measured in Ussing chamber analyses of 2D 
monolayers under CCH (2D ΔIsc-eqCCH), IF + CCH (2D ΔIsc-eq(max), inh172 following IF + CCH ((2D ΔIsc-eq(inh172)); activated short circuit currents measured in Ussing 
chamber analyses of rectal biopsies under IF + CCH (Biopsy ΔIsc-eq(max)); activated short circuit currents measured in Ussing chambers of control 2D monolayers under IF (2D 
ΔIsc-eqIF(DMSO)) and treated 2D monolayers under IF + VX-770 (2D ΔIsc-eq(661/770); sweat [Cl
-] (mmol/L); fecal elastase E1 (FEE, µg/g stool; forced expiratory volume in 1 sec 
(FEV1, %); AUC values measured in FIS assay at just  [Fsk] = 0.02, 0.128, 0.8 e 5 µM (AUC [Fsk] = 0.02, 0.128, 0.8, 5) and with VX-661/770 (AUC 661/770 [Fsk] = 0.02, 0,128, 
























































CFL54 -2,18 -4,65 -5,73 2,42 -9,98 -10,67 94,3 351 70 309,27 452,93 361,21 616,57 288,85 725,30 1892,67 2489,33 
CFL59 -4,67 -26,13 -29,93 26,59 -34,59 NA 56,5 500 99 221,44 512,67 1394,90 1875,07 NA NA NA NA 
CFL61 -3,06 -0,60 -1,81 0,86 6,46 -1,03 82,7 1 95 NA NA NA NA NA NA NA NA 
CFL65 -4,18 -5,30 -5,32 2,31 5,31 -7,62 117 1 89 329,16 322,63 311,90 308,30 214,87 606,23 1330,33 1563,67 
CFL70 -4,52 -2,22 -3,71 2,14 13,86 -7,11 112 30 101 277,63 480,23 416,77 752,27 592,77 638,33 1518,67 1708,00 
CFL75 -1,74 -5,38 -7,02 2,80 2,88 -33,07 91 500 124 23,59 91,72 1347,60 2574,00 7,10 834,87 2982,67 3585,00 




4.5.1 Correlations between 2D Model and Fresh Tissue 
 
 One of the main objectives of the present work was to assess if the 2D-intestinal epithelial 
monolayers could be used to measure CFTR basal activity to possibly replace CFTR function analysis of 
fresh rectal biopsies. Therefore, correlation analyses among different CFTR function parameters used, 
namely the cAMP (I/F)- and cholinergic (CCH)-mediated activated short-circuit currents (Isc-eq IF+CCH) 
measured in the Ussing chamber on both 2D-monolayers and fresh tissue, were established. The results 
show a significant correlation between Biopsy ΔIsc-eq (max) vs 2D ΔIsc-eq (max) (p<0.05) (Table 4.4). 
 
Table 4.4 – Correlation data between activated short circuit currents measured in 2D-monolayers and rectal biopsies. 
Parameter 1 refers to the sum of activated short circuit currents measured ex vivo in rectal biopsies upon addition of IF and CCH 
(Biopsy ΔIsc-eq (max)). Parameter 2 refers to the activated short circuit currents measured in 2D-monolayers in response to CCH 
without Indo (2D ΔIsc-eq (CCH)), IBMX/Fsk (2D ΔIsc-eq(IF)), the sum of the last two currents (2D ΔIsc-eq (max)) and inh172 
addition after the last response (2D ΔIsc-eq (inh172)). Pearson correlation coefficients (r), Spearman correlation coefficients (ρ), 
respective p –value and sample number (n) are denoted. Significant p –values are highlighted in bold. NA – Not Aplicable. 





2D ΔIsc-eq(CCH) 0.3119562 NA 0.4957952 7 
2D ΔIsc-eq(IF) NA 0.7500000 0.0521814 7 
2D ΔIsc-eq (max) NA 0.8214286 0.0234488 7 
2D ΔIsc-eq 
(inh172) 
NA -0.6428571 0.1193924 7 
 
 The results indicate that there is a positive correlation between the cholinergic-mediated co-
activated current measured in the 2D-monolayers and the same response measured ex vivo in the rectal 
biopsies (Figure 4.27). We can conclude that the maximal activation of CFTR function in the 2D-
monolayers can predict the maximal activation of CFTR in the rectal biopsies, making the 2D-monolayers 




Figure 4.27 – Correlation between CCH-induced short circuit currents following IBMX/Fsk administration to 2D-
monolayers and rectal biopsies. Plot of 2D ΔIsc-eq (max) (μA/cm
2) determined in in vitro Ussing chamber measurements of 2D-
monolayers and Biopsy ΔIsc-eq (max) (μA/cm
2) determined in ex vivo measurements of rectal biopsies from individual with CF 
(Spearman ρ = 0.82, p –value = 0.023, n = 7). A degree of CFTR genotype severity was determined from previously proposed CF 
diagnosis from rectal biopsy analyzes as mild (green) and severe (red). Grey line represents the linear regression of the data. Grey 
area represents the 95% confidence interval. 
 
4.5.2 Correlations between 2D- and 3D-models 
 
 As one of the objectives of this MSc thesis was to ascertain if the 2D-intestinal epithelial 
monolayers could be used to measure the level of CFTR functional rescue by the currently approved 
modulators, a correlation analysis with the already implemented FIS assay was established. Moreover, we 
aimed to determine if the basal CFTR activity measured with the condition of ‘Fsk alone’ in the FIS assay 
correlates with the basal CFTR activity measured in the 2D-monolayers. To that end, the activated short-
circuit currents measured in the 2D-monolayers using the Ussing chamber were correlated with the AUC 
FIS assay measurements in the 3D-intestinal organoids. For this, data summarized in Table 4.3 were used 
and the correlation results are in Table 4.5. The strongest correlations were found between 2D ΔIsc-eq (max) 






Table 4.5 – Correlation analyzes between activated short circuit currents measured in 2D-monolayers and organoid 
swelling. Correlation analyses were established between parameters 1 and 2. Parameter 1 refers to the activated short circuit 
currents measured in 2D monolayers in response to CCH (2D ΔIsc-eq (CCH)), IBMX/Fsk (2D ΔIsc-eq(IF)), the sum of the last two 
currents (2D ΔIsc-eq (max)), inh172 addition after the last response (2D ΔIsc-eq (inh172)), IF addition in the control DMSO 
monolayers, IF and VX-770 addition in monolayers treated with VX-661 (μA/cm2). Parameter 2 refers to the organoid swelling 
expressed as the AUC of the organoid surface area increase (baseline = 100%; t = 60 min) at [Fsk] = 0.02, 0.128, 0.8, 5 µM in the 
control condition (Fsk only) and at [Fsk] = 0.8 µM for the organoids treated with VX-661/770. Pearson correlation coefficients 
(r), Spearman correlation coefficients (ρ), respective p –value and sample number (n) are denoted. Significant p –values are 
highlighted in bold. NA – Not Aplicable 
Parameter 1 Parameter 2 Pearson r Spearman ρ p -value n 
 
 
2D ΔIsc-eq (CCH) 
AUC [Fsk] = 0.02 0.1103930 NA 0.7330893 6 
AUC [Fsk] = 0.128 -0.7220648 NA 0.1051370 6 
AUC [Fsk] = 0.8 NA -0.6000000 0.8350831 6 




AUC [Fsk] = 0.02 0.2121227 NA 0.6865882 6 
AUC [Fsk] = 0.128 -0.4459038 NA 0.3754739 6 
AUC [Fsk] = 0.8 NA -0.7714286 0.0723965 6 
AUC [Fsk] = 5 -0.4740884 NA 0.3421455 6 
 
 
2D ΔIsc-eq (max) 
AUC [Fsk] = 0.02 0.2434739 NA 0.6420057 6 
AUC [Fsk] = 0.128 -0.4495997 NA 0.3710414 6 
AUC [Fsk] = 0.8 NA -0.8285714 0.0415627 6 
AUC [Fsk] = 5 -0.5056018 NA 0.3062217 6 
 
 
2D ΔIsc-eq (inh172) 
AUC [Fsk] = 0.02 -0.1479237 NA 0.7797329 6 
AUC [Fsk] = 0.128 0.4704481 NA 0.3463880 6 
AUC [Fsk] = 0.8 NA 0.4857143 0.3287230 6 
AUC [Fsk] = 5 0.4325278 NA 0.3916671 6 
 
 
2D ΔIsc-eq (IF (661/770)) 
AUC 661/770 [Fsk] = 0.02 0.6813709 NA 0.2052722 5 
AUC 661/770 [Fsk] = 0.128 -0.3985623 NA 0.5063099 5 
AUC 661/770 [Fsk] = 0.8 -0.7951730 NA 0.1077953 5 
AUC 661/770 [Fsk] = 5 -0.8825652 NA 0.0474490 5 
 
 These results indicate that the cholinergic-mediated co-activated currents measured in the 2D-
monolayers correlate well with the basal CFTR activity measured in the FIS assay at [Fsk] = 0.8 µM 
(Figure 4.28), in a negative trend meaning the more negative the current (i.e., more CFTR activity), more 





Figure 4.28 - Correlation between CCH-induced short circuit currents following IBMX/Fsk administration to 2D-
monolayers and the AUC of organoid swelling at [Fsk] = 0.8 µM. Plot of 2D ΔIsc-eq (max) (μA/cm
2) determined in in vitro 
Ussing chamber measurements of 2D-monolayers from individuals’ 3D organoids and matched organoid swelling measurements 
in FIS assay expressed as AUC of organoid surface area increase (baseline = 100%, t = 60 min) for [Fsk] = 0.8 (Spearman ρ = -
0.83, p –value =  0.042, n = 6). A degree of CFTR genotype severity was determined from previously proposed CF diagnosis from 
rectal biopsy analyzes as mild (green) and severe (red). Grey line represents the linear regression of data. Grey area represents de 
confidence interval of 95%. 
 
 For the drug tests in the 2D-monolayers, we could see a correlation between the effects of the 
combination VX-661/770 in monolayers stimulated with IF (100 µM, 0.8 µM) with the AUC of VX-




Figure 4.29 - Correlation between VX-770-induced short circuit currents following IBMX/Fsk in VX-661 treated 2D-
monolayers and the AUC of VX-661/770-treated organoid swelling at [Fsk] = 5 µM. Plot of 2D ΔIsc-eq (IF (DMSO)) (μA/cm
2) 
determined in in vitro Ussing chamber measurements of 2D-monolayers from individuals’ 3D-organoids under IBMX/Fsk (100 
µM, 0.8 µM) and matched organoid swelling measurements in FIS assay expressed as AUC of organoid surface area increase 
(baseline = 100%, t = 60 min) for [Fsk] = 0.128 (Pearson r = -0.88, p –value = 0.047, n = 5). A degree of CFTR genotype severity 
was determined from previously proposed CF diagnosis from rectal biopsy analyzes as mild (green) and severe (red). Grey line 
represents the linear regression of data. Grey area represents de confidence interval of 95%. 
 
 Overall, these results show that there are good correlations between the 2D- and the 3D-models 
for measurements of both basal CFTR activity and CFTR function rescue with approved CFTR 
modulators. So, in the future, there is a possibility to use these 2D-monolayers as a complement to the FIS 
assay in the prediction of individual-specific drug response.  
 
4.5.3 Correlations between Different CFTR Function Parameters Measured in the 
2D Monolayers with Clinical Data and Established CF Biomarkers 
 
 In order to assess if the 2D-model in study could be used to predict disease severity, correlation 
analyses were established between the short circuit-currents measured in the 2D-intestinal monolayers in 
the Ussing chamber and matched to the individual clinical data and values from other established CF 
biomarkers. Correlations were found between FEE vs 2D ΔIsc-eq(IF) (p<0.05) and between FEE vs 2D 
ΔIsc-eq (max) (p<0.01), being the last one the strongest and most significant. 
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Table 4.6 – Correlation data between the activated short circuit currents measured in the 2D monolayers and the 
individuals’ clinical data. Parameter 1 refers to the Sweat [Cl-] (mmol/L), fecal elastase E1 (FEE, µg/g stool and forced 
expiratory volume in 1 sec (FEV1, %). Parameter 2 refers to the activated short circuit currents measured in 2D monolayers in 
response to CCH (2D ΔIsc-eq (CCH)), IBMX/Fsk (2D ΔIsc-eq(IF)), the sum of the last two currents (2D ΔIsc-eq (max)), inh172 
addition after the last response (2D ΔIsc-eq (inh172)) and IF addition in the control DMSO monolayers. Pearson correlation 
coefficients (r), Spearman correlation coefficients (ρ), respective p –value and sample number (n) are denoted. Significant p –
values are highlighted in bold. NA – Not Aplicable 






2D ΔIsc-eq(CCH) 0.2619717 NA 0.5703656 7 
2D ΔIsc-eq(IF) NA 0.3571429 0.4316114 7 
2D ΔIsc-eq (max) NA 0.4285714 0.3373683 7 




2D ΔIsc-eq(CCH) 0.1315618 NA 0.7785816 7 
2D ΔIsc-eq(IF) NA -0.7671932 0.0441075 7 
2D ΔIsc-eq (max) NA -0.8794654 0.0090698 7 




2D ΔIsc-eq(CCH) -0.2458050 NA 0.5951997 7 
2D ΔIsc-eq(IF) NA -0.4285714 0.3373683 7 
2D ΔIsc-eq (max) NA -0.3928571 0.3833169 7 
2D ΔIsc-eq (inh172) NA 0.1071429 0.8191509 7 
 
 With these correlation analyses, the results show that the cAMP-activated currents and cholinergic 
co-activated currents measured in the 2D-monolayers could be good predictors of the individual’s 
pancreatic status (Figure 4.30). The other clinical parameters did not produce significant correlations. 






Figure 4.30 – Correlation among IBMX/Fsk-induced short circuit currents and CCH-induced short circuit current 
following IBMX/Fsk, and individuals’ FEE values. Plot of the individuals’ FEE measurements (µg/ g stool) and: (A) 2D ΔIsc-
eq(IF) determined in Ussing chamber measurements of 2D monolayers under CCH (100 µM) following IBMX/Fsk stimulation 
(100 µM, 2 µM) (Spearman ρ = -0.88,  p –value = 0.0091, n = 7); (B) 2D ΔIsc-eq (max) determined in Ussing chamber 
measurements of 2D monolayers under IBMX/Fsk (100µM, 2 µM) (Spearman ρ = -0.77,  p –value = 0.044, n = 7). A degree of 
CFTR genotype severity was determined from previously proposed CF diagnosis from rectal biopsy analyzes as mild (green) and 





5. Conclusion and Future Perspectives 
 
 In this MSc project, we explored a new and exciting ex vivo model that consists in growing 2D-
monolayers of intestinal epithelial cells derived from 3D-intestinal organoids of individuals with CF and 
healthy non-CF controls. This is a versatile model, since it can remain in culture as a monolayer of 
undifferentiated stem cells or can be differentiated into several cell types of the colon epithelium. By 
assessing the differentiation process, we could conclude that these cells differentiate in a very short time, 
just 6 days in culture. However, the differentiation process results in a severe reduction of CFTR protein 
levels. Measuring the basal activity in wt/wt 2D-monolayers, we observed that cAMP-stimulated CFTR-
mediated Cl
-
 secretion was diminished in differentiated monolayers. This means that, unexpectedly, the 
undifferentiated cells are the ones that have the higher capability to secrete CFTR-mediated Cl
-
 and fluid. 
Thus, for CFTR function studies using 2D-intestinal monolayers, the undifferentiated monolayers were 
used in subsequent studies to compare these cells with the rectal biopsies and the 3D-organoids, which are 
more established models to study CFTR function.  
 With the 3D-intestinal organoid model, CFTR function and rescue of function with approved 
modulators can be assessed by measuring the amount of organoid swelling when cAMP is increased, by 
using the so called FIS assay. The 2D-monolayers, for instance, can be used for the same CFTR function 
assay but, in this case, bioelectrical measurements are used resorting to micro-Ussing chambers. 
Therefore, CFTR functional rescue with the already approved modulators can be assessed through 
transepithelial electrical current measurements of Cl
-
 secretion, being a more direct and sensitive approach 
than the measurement of fluid secretion to the lumen of the organoids. Indeed, we could conclude that 
there was rescue of CFTR function with approved modulator drugs in materials from 4 out of 7 
individuals with CF analyzed, which should be an incentive to expand this assay to more individuals with 
CF bearing different mutations. 
 A method to complement CF diagnosis and to measure basal CFTR activity in fresh tissue which 
is already implemented in specialized labs is the diagnosis protocol using rectal biopsies. In this assay, Cl
-
 
secretion is evaluated through bioelectrical measures in micro-Ussing chambers of fresh rectal biopsies 
from individual with CF. This assay has its limitations, such as a short time limit (<6h) to perform the 
assay before the biopsies are degraded and the fact that not every biopsy has enough quality to generate 
electrical responses in the Ussing chamber. However, there is a high success rate for the generation of 
intestinal 3D-organoids from the biopsy even 24h post-collection. Thus, 2D-intestinal monolayers can be 
grown from these intestinal 3D-organoids and be used to perform the same basal CFTR activity 
measurements in the fresh biopsies in the Ussing chamber.  
 Correlation analyses between CFTR function parameters measured in the 2D-monolayers, with 
the ones measured in the 3D-organoids and fresh tissue showed that these are in fact well correlated. We 
observed that the 2D-monolayers can predict the maximal activation of CFTR function in the rectal 
biopsies, making the 2D-model a good one to replace or complement the rectal biopsy assay for 
diagnosis/prognosis of CF. Moreover, the basal CFTR activity measured in the 3D-organoids with the FIS 
assay also correlates with basal CFTR activity measurements in the 2D-models. Additionally, Ussing 
chamber measurements of CFTR function rescue with the combination VX-661/770 in 2D-monolayers 
correlate well with the FIS assay of matched individuals’ 3D organoids with the same treatment. This is 
68 
 
very important since 2D-monolayers can, thus, be used to complement individual-specific drug response 
measured with the FIS assay. Accordingly, we can use the 2D-model to deliver a personalized 
medicine/theranostics approach to provide each individual with CF with the right drug. Lastly, to assess 
the relevance of the 2D-model in predicting clinical outcomes, correlations with clinical parameters and 
other established CF biomarkers were established. It was found that CFTR function parameters measured 
in the 2D-monolayers correlate significantly with FEE values of the individuals with CF studied here, thus 
making the 2D-monolayers a possible good model to predict disease severity, i.e. CF prognosis. Overall, 
the results can be perceived as an incentive for the further study of these 2D-monolayers and their use in 
the CF field. For this purpose, the numbers of samples from individual with CF should be increased, so as 
to establish better correlations to further validate this 2D-model for the assessment of CFTR function and 
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